Drugs / Insulin
Insulin
also known as
human insulin · regular insulin · NPH Insulin · Technosphere Insulin · regular human insulin · Actrapid · Humulin R · Exubera · +90 more
Protein / enzyme biologic targets IGF1R
Regulatory milestones approvals, filings & regulatory actions · 9 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Label expansions (3) | US (FDA) | AFREZZA | — | 2017-09-29 – 2026-05-29 | fda.gov ↗ |
| Refused (EMA) | EU (EMA) | Solumarv | — | 2016-02-11 | europa.eu ↗ |
| Label expansions (2) | US (FDA) | HUMULIN R PEN | — | 1994-03-31 – 2011-03-25 | fda.gov ↗ |
| Label expansion | US (FDA) | NOVOLIN R | — | 2005-10-21 | fda.gov ↗ |
| Approved | EU (EMA) | Insuman | — | 1997-02-21 | europa.eu ↗ |
| Approved | US (FDA) | HUMULIN R PEN | — | 1982-10-28 | fda.gov ↗ |
Trials 371 · started per year
today
US approved 1982
EU approved 1997
1
1
1
1
2
1
2
5
4
2
17
6
13
13
28
22
18
14
10
16
8
19
14
8
11
12
16
14
12
13
13
14
11
14
8
3
1982198319841985198619871988198919901991199219931994199519961997199819992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027202820292030
Also used as a comparator or background therapy in 313 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 07 trials | ||||||
| Phase 0 | NCT06741566 Comparator | Dec 2024 → May 2026 overdue | — | Minia University | Recruiting | No outcome recorded |
| Phase 0 | NCT04742023 Background | Apr 2020 → Nov 2023 | diabetes mellitus | Northwell Health | Completed | No outcome recorded |
| Phase 0 | NCT04133922 Comparator | Oct 2019 → Oct 2023 | type 1 diabetes mellitus | University of Virginia | Withdrawn | No outcome recorded |
| Phase 0 | NCT03520569 Comparator | Feb 2019 → Apr 2021 | arterial disorder | University of Virginia | Completed | No outcome recorded |
| Phase 0 | NCT03738852 Background | Nov 2018 → Aug 2023 | type 1 diabetes mellitus | Yale University | Completed | No outcome recorded |
| Phase 0 | NCT03469492 Comparator | Jan 2018 → Mar 2020 | hyperglycemia | Yale University | Completed | No outcome recorded |
| Phase 0 | NCT00993057 Comparator | Oct 2009 → Aug 2012 | brain aneurysm, brain neoplasm | Northwestern University | Completed | No outcome recorded |
| Phase 135 trials | ||||||
| Phase 1 | NCT07364669 Comparator | Oct 2024 → Feb 2025 | — | Laboratorios PiSA | Completed | No outcome recorded |
| Phase 1 | NCT06519604 Comparator | Jul → Sep 2024 overdue | diabetes mellitus | Shanghai Jiao Tong University School of Medicine | Active not recruiting | No outcome recorded |
| Phase 1 | NCT05331859 Comparator | May → Aug 2022 | corneal disorder | Benha University | Unknown | No outcome recorded |
| Phase 1 | NCT06153329 Comparator | Jun 2021 → Jun 2022 | — | Tonghua Dongbao Pharmaceutical Co.,Ltd | Completed | No outcome recorded |
| Phase 1 | NCT05441631 Comparator | Apr → Jul 2020 | COVID-19, hyperglycemia | Benha University | Completed | No outcome recorded |
| Phase 1 | NCT04975022 Comparator | Dec 2019 → Aug 2020 | — | Beijing Hospital | Completed | No outcome recorded |
| Phase 1 | NCT04022317 Comparator | Jun → Sep 2019 | — | Biocon Limited | Completed | No outcome recorded |
| Phase 1 | NCT03916640 Comparator | Jan → Mar 2019 | type 1 diabetes mellitus | Adocia | Completed | No outcome recorded |
| Phase 1 | NCT03241706 Comparator | Aug 2018 → May 2028 expected | hypoglycemia | Jason Winnick | Active not recruiting | No outcome recorded |
| Phase 1 | NCT03512236 Comparator | Apr 2018 → Feb 2019 | type 1 diabetes mellitus | Adocia | Completed | No outcome recorded |
| Phase 1 | NCT03234491 Comparator | Nov 2017 → Jul 2019 | hyperglycemia | Yale University | Completed | No outcome recorded |
| Phase 1 | NCT03170544 Background | Aug 2017 → Nov 2018 | type 1 diabetes mellitus, type 2 diabetes mellitus | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 1 | NCT02635243 Background | Apr → Nov 2016 | type 1 diabetes mellitus | Sanofi | Withdrawn | No outcome recorded |
| Phase 1 | NCT02500979 Background | Aug 2015 → Aug 2016 | type 1 diabetes mellitus | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT02328040 Comparator | Sep 2014 → Jan 2016 | type 1 diabetes mellitus | Albert Einstein College of Medicine | Completed | No outcome recorded |
| Phase 1 | NCT02237053 Comparator | Sep 2014 → Jun 2015 | abnormality of glucagon secretion, obesity disorder | AdventHealth Translational Research Institute | Completed | No outcome recorded |
| Phase 1 | NCT02109029 Comparator | Apr 2014 → Mar 2015 | type 1 diabetes mellitus | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT01581736 Background | Apr 2012 → Apr 2016 | obesity disorder, type 2 diabetes mellitus | Mayo Clinic | Terminated | No outcome recorded |
| Phase 1 | NCT01490762 Comparator | Dec 2011 → May 2012 | — | Mannkind Corporation | Completed | No outcome recorded |
| Phase 1 | NCT01311076 Comparator | Mar → Dec 2011 | type 1 diabetes mellitus | Takeda | Completed | No outcome recorded |
| Phase 1 | NCT01300260 Background | Feb → Aug 2011 | type 2 diabetes mellitus | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT00772265 Comparator | Sep 2010 → Mar 2011 | diabetes mellitus | Wockhardt | Completed | No outcome recorded |
| Phase 1 | NCT01114750 Comparator | Apr → Aug 2010 | diabetes mellitus | Bows Pharmaceuticals AG | Suspended | No outcome recorded |
| Phase 1 | NCT00790153 Comparator | Nov 2008 → Feb 2009 | type 2 diabetes mellitus | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT00752180 Comparator | Aug 2008 → Mar 2009 | diabetes mellitus | Wockhardt | Completed | No outcome recorded |
| Phase 1 | NCT00719108 Comparator | Jul → Sep 2008 | diabetes mellitus | Wockhardt | Completed | No outcome recorded |
| Phase 1 | NCT01031888 Comparator | Mar 2008 → Dec 2009 | corneal disorder | National Taiwan University Hospital | Completed | No outcome recorded |
| Phase 1 | NCT00596063 Comparator | Jan → Feb 2008 | diabetes mellitus | Wockhardt | Completed | No outcome recorded |
| Phase 1 | NCT00705536 Comparator | Dec 2007 → Feb 2008 | diabetes mellitus | Halozyme Therapeutics | Completed | No outcome recorded |
| Phase 1 | NCT00576394 Comparator | Oct 2006 → Jun 2015 | glucose metabolism disease | American Heart Association | Completed | No outcome recorded |
| Phase 1 | NCT02012166 Background | Jul → Dec 2005 | type 2 diabetes mellitus | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 1 | NCT00460499 Comparator | Jul 2004 → Mar 2015 | glucose metabolism disease | American Heart Association | Completed | No outcome recorded |
| Phase 1 | NCT00513643 Comparator | Apr → Jun 2002 | diabetes mellitus | Profil Institute for Metabolic Research GmbH | Completed | No outcome recorded |
| Phase 1 | NCT01511159 Comparator | Oct → Dec 2001 | diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1 | NCT00511979 Comparator | Aug 1999 → Feb 2000 | — | Mannkind Corporation | Completed | No outcome recorded |
| Phase 1/213 trials | ||||||
| Phase 1/2 | NCT04635774 Comparator | Feb 2021 → Nov 2023 | delirium | University of Kansas Medical Center | Withdrawn | No outcome recorded |
| Phase 1/2 | NCT03011021 Background | Jan 2017 → Jun 2025 | type 1 diabetes mellitus | Second Xiangya Hospital of Central South University | Unknown | No outcome recorded |
| Phase 1/2 | NCT02932826 Background | Oct 2016 → Jun 2025 | type 1 diabetes mellitus | Second Xiangya Hospital of Central South University | Unknown | No outcome recorded |
| Phase 1/2 | NCT02739906 Comparator | Apr → Aug 2016 | type 1 diabetes mellitus | Adocia | Completed | No outcome recorded |
| Phase 1/2 | NCT02154477 Comparator | Dec 2014 → Dec 2017 | hypogonadotropic hypogonadism | Texas Tech University Health Sciences Center | Completed | No outcome recorded |
| Phase 1/2 | NCT01496339 Comparator | Jan 2012 → Dec 2013 | type 1 diabetes mellitus | S-Evans Biosciences Co., Ltd. | Unknown | No outcome recorded |
| Phase 1/2 | NCT01719640 Background | Jan 2011 → Jan 2013 | type 2 diabetes mellitus | Fuzhou General Hospital | Completed | No outcome recorded |
| Phase 1/2 | NCT01159847 Background | Jan 2010 → Jul 2012 | type 1 diabetes mellitus | European Foundation for the Study of Diabetes | Completed | No outcome recorded |
| Phase 1/2 | NCT00990444 Comparator | Sep 2009 → Sep 2010 | diabetes mellitus | Bows Pharmaceuticals AG | Suspended | No outcome recorded |
| Phase 1/2 | NCT01786707 Background | Jul 2009 → Mar 2011 | type 2 diabetes mellitus | Rodolfo Alejandro | Completed | No outcome recorded |
| Phase 1/2 | NCT01374854 Background | Jan 2009 → Dec 2010 | type 1 diabetes mellitus | Fuzhou General Hospital | Unknown | No outcome recorded |
| Phase 1/2 | NCT00812487 Comparator | Jan 2009 → Aug 2012 | congestive heart failure, diabetes mellitus | Kathleen Dungan | Completed | No outcome recorded |
| Phase 1/2 | NCT01295177 Comparator | Jan 2004 → Aug 2007 | diabetes mellitus | University of Campinas, Brazil | Completed | No outcome recorded |
| Phase 231 trials | ||||||
| Phase 2 | NCT06762314 Comparator | Jan 2025 → Sep 2027 expected | diabetes mellitus | Mostafa Bahaa | Recruiting | No outcome recorded |
| Phase 2 | NCT06111586 Background | Dec 2023 → Apr 2027 expected | type 1 diabetes mellitus | Sanofi | Active not recruiting | No outcome recorded |
| Phase 2 | NCT05742243 Comparator | Feb 2023 → Sep 2025 | type 1 diabetes mellitus | Melbourne Health | Completed | No outcome recorded |
| Phase 2 | NCT03277222 Comparator | Nov 2018 → Apr 2019 | AIDS dementia complex | University of Calgary | Terminated | No outcome recorded |
| Phase 2 | NCT03337477 Comparator | Feb → Dec 2018 | — | AstraZeneca | Completed | No outcome recorded |
| Phase 2 | NCT03111433 Background | Mar 2017 → Jan 2018 | type 1 diabetes mellitus | Ain Shams University | Completed | No outcome recorded |
| Phase 2 | NCT02774876 Comparator | Jun 2016 → Sep 2017 | type 1 diabetes mellitus | Montreal Clinical Research Institute | Completed | No outcome recorded |
| Phase 2 | NCT02810392 Comparator | Apr 2016 → Mar 2020 | stroke disorder | Wake Forest University Health Sciences | Completed | No outcome recorded |
| Phase 2 | NCT02490085 Comparator | Oct 2015 → Sep 2018 | type 2 diabetes mellitus | Montreal Clinical Research Institute | Completed | No outcome recorded |
| Phase 2 | NCT02164032 Comparator | Sep 2014 → Jul 2016 | — | Medical University of Vienna | Unknown | No outcome recorded |
| Phase 2 | NCT02028871 Comparator | Jul 2014 → May 2016 | substance withdrawal syndrome | Ajna Hamidovic | Completed | No outcome recorded |
| Phase 2 | NCT01755416 Comparator | Jan 2013 → Jan 2015 | type 1 diabetes mellitus | Albert Einstein College of Medicine | Completed | No outcome recorded |
| Phase 2 | NCT01516138 Comparator | Feb 2012 → Mar 2013 | — | Xijing Hospital | Unknown | No outcome recorded |
| Phase 2 | NCT01469559 Comparator | Aug 2011 → Jul 2012 | diabetic polyneuropathy | University of Calgary | Completed | No outcome recorded |
| Phase 2 | NCT00916357 Comparator | Jul → Nov 2009 | type 2 diabetes mellitus | Halozyme Therapeutics | Completed | No outcome recorded |
| Phase 2 | NCT01071772 Background | Apr 2009 → Jul 2010 | heart failure, type 2 diabetes mellitus | University of Aarhus | Completed | No outcome recorded |
| Phase 2 | NCT00837759 Background | Feb 2009 → Mar 2011 | type 1 diabetes mellitus | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Terminated | No outcome recorded |
| Phase 2 | NCT00850096 Comparator | Jan 2009 → Mar 2010 | type 2 diabetes mellitus | CPEX Pharmaceuticals Inc. | Completed | No outcome recorded |
| Phase 2 | NCT00770640 Background | Aug 2008 → Jun 2010 | type 2 diabetes mellitus | Takeda | Completed | No outcome recorded |
| Phase 2 | NCT00807651 Comparator | Feb 2008 → Jun 2016 | type 1 diabetes mellitus | Shanghai Jiao Tong University School of Medicine | Completed | No outcome recorded |
| Phase 2 | NCT00553488 Comparator | Sep → Dec 2007 | type 1 diabetes mellitus | Becton, Dickinson and Company | Completed | No outcome recorded |
| Phase 2 | NCT00336674 Comparator | Dec 2006 → Nov 2019 | type 1 diabetes mellitus | Melbourne Health | Completed | No outcome recorded |
| Phase 2 | NCT00437164 Background | Sep → Nov 2006 | type 2 diabetes mellitus | GlaxoSmithKline | Terminated | No outcome recorded |
| Phase 2 | NCT00282867 Comparator | May 2006 → Feb 2008 | hyperglycemia, ischemic stroke | University of Virginia | Completed | No outcome recorded |
| Phase 2 | NCT00110864 Background | May 2005 → Apr 2007 | type 2 diabetes mellitus | Wellstat Therapeutics | Completed | No outcome recorded |
| Phase 2 | NCT00099515 Background | Nov 2004 → Sep 2005 | type 2 diabetes mellitus | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 2 | NCT00511719 Comparator | Feb → Apr 2004 | type 2 diabetes mellitus | Mannkind Corporation | Completed | No outcome recorded |
| Phase 2 | NCT00099333 Comparator | Feb 2004 → Aug 2005 | type 2 diabetes mellitus | AstraZeneca | Completed | No outcome recorded |
| Phase 2 | NCT00063128 Comparator | Apr 2003 → Apr 2004 | type 1 diabetes mellitus | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 2 | NCT00654121 Comparator | Feb 2000 → Apr 2004 | type 1 diabetes mellitus | University Hospital Brussels | Completed | No outcome recorded |
| Phase 2 | NCT00814008 Background | Mar 1999 → Apr 2000 | retinal disorder, type 1 diabetes mellitus | Medical University of Vienna | Completed | No outcome recorded |
| Phase 2/38 trials | ||||||
| Phase 2/3 | NCT07675499 Comparator | Aug 2026 → May 2029 expected | type 2 diabetes mellitus | Rutgers, The State University of New Jersey | Recruiting | No outcome recorded |
| Phase 2/3 | NCT07548996 Background | Apr 2026 → Dec 2028 expected | type 1 diabetes mellitus | Nanjing Medical University | Recruiting | No outcome recorded |
| Phase 2/3 | NCT05565976 Background | Aug 2020 → Dec 2024 | cognitive impairment with or without cerebellar ataxia, ischemic stroke, metabolic syndrome X, vascular dementia | Jaime Daniel Mondragon | Unknown | No outcome recorded |
| Phase 2/3 | NCT03899402 Background | May 2019 → Jan 2026 overdue | type 1 diabetes mellitus | State University of New York at Buffalo | Active not recruiting | No outcome recorded |
| Phase 2/3 | NCT02432976 Comparator | May 2015 → Jan 2017 | — | Centre Hospitalier Universitaire de Besancon | Completed | No outcome recorded |
| Phase 2/3 | NCT01969149 Comparator | Jan → Dec 2015 | hyperglycemia | Centre Hospitalier Universitaire de Besancon | Completed | No outcome recorded |
| Phase 2/3 | NCT01855763 Comparator | Dec 2008 → Dec 2013 | gestational diabetes, type 2 diabetes mellitus | Dow University of Health Sciences | Unknown | No outcome recorded |
| Phase 2/3 | NCT01087866 Comparator | Jun 2005 → Aug 2009 | gestational diabetes | University of Oulu | Completed | No outcome recorded |
| Phase 357 trials | ||||||
| Phase 3 | NCT06601101 Comparator | Aug 2024 → Oct 2025 overdue | keratoconus | University of Campinas, Brazil | Recruiting | No outcome recorded |
| Phase 3 | NCT05746676 Comparator | Jan → Aug 2023 | periodontal disorder | October University for Modern Sciences and Arts | Unknown | No outcome recorded |
| Phase 3 | NCT05305794 Background | Jul 2022 → Aug 2028 expected | diabetes mellitus | Centre Hospitalier Universitaire Dijon | Recruiting | No outcome recorded |
| Phase 3 | NCT04029480 Background | Oct 2019 → Apr 2025 | type 2 diabetes mellitus | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 3 | NCT03429543 Background | Mar 2018 → Oct 2022 | type 2 diabetes mellitus | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 3 | NCT03419624 Background | Feb 2018 → Apr 2019 | obesity disorder, type 2 diabetes mellitus | University Medical Center Hamburg-Eppendorf | Terminated | No outcome recorded |
| Phase 3 | NCT03841591 Comparator | Feb → Dec 2018 | gestational diabetes | Ain Shams University | Completed | No outcome recorded |
| Phase 3 | NCT03651531 Comparator | Jan 2018 → Jul 2019 | gestational diabetes | Women and Infants Hospital of Rhode Island | Terminated | No outcome recorded |
| Phase 3 | NCT04012775 Comparator | Apr 2017 → Sep 2018 | type 2 diabetes mellitus | Geropharm | Completed | No outcome recorded |
| Phase 3 | NCT02897349 Background | Sep 2016 → Jan 2019 | type 2 diabetes mellitus | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 3 | NCT03320694 Comparator | Feb 2016 → Jun 2017 | gestational diabetes | Services Institute of Medical Sciences, Pakistan | Completed | No outcome recorded |
| Phase 3 | NCT02607943 Comparator | Dec 2015 → Jul 2018 | hyperglycemia, stroke disorder | National Taiwan University Hospital | Unknown | No outcome recorded |
| Phase 3 | NCT02518945 Comparator | Aug → Dec 2015 | type 1 diabetes mellitus | University at Buffalo | Completed | No outcome recorded |
| Phase 3 | NCT02080377 Comparator | Jul 2014 → Oct 2015 | gestational diabetes | University of Edinburgh | Completed | No outcome recorded |
| Phase 3 | NCT02033889 Background | Dec 2013 → Aug 2017 | type 2 diabetes mellitus | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 3 | NCT01850615 Background | Sep 2013 → Nov 2014 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 3 | NCT01798706 Background | Jun 2013 → Feb 2015 | type 2 diabetes mellitus | Sanofi | Completed | No outcome recorded |
| Phase 3 | NCT01698775 Background | Oct 2012 → Jan 2016 | type 2 diabetes mellitus | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 3 | NCT01590797 Background | Jul 2012 → Jun 2014 | type 2 diabetes mellitus | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 3 | NCT01572740 Background | Apr → Nov 2012 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 3 | NCT01565941 Comparator | Apr 2012 → Sep 2016 | heart failure, respiratory failure | Boston Children's Hospital | Completed | No outcome recorded |
| Phase 3 | NCT01485614 Background | Feb 2012 → Oct 2019 | type 2 diabetes mellitus | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 3 | NCT01521962 Comparator | Feb 2012 → Mar 2013 | diabetes mellitus | Takeda | Completed | No outcome recorded |
| Phase 3 | NCT01760447 Background | Dec 2011 → Sep 2019 | type 2 diabetes mellitus | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 3 | NCT01353469 Comparator | May 2011 → Nov 2012 | type 2 diabetes mellitus | Sanofi | Completed | No outcome recorded |
| Phase 3 | NCT01136746 Comparator | Mar → Nov 2011 | hyperglycemia | Eli Lilly and Company | Terminated | No outcome recorded |
| Phase 3 | NCT01223131 Comparator | Feb 2011 → Mar 2014 | type 1 diabetes mellitus | Sanofi | Completed | No outcome recorded |
| Phase 3 | NCT01215331 Comparator | Aug 2010 → Apr 2014 | gestational diabetes | University of Sherbrooke | Completed | No outcome recorded |
| Phase 3 | NCT01106651 Background | Jun 2010 → Nov 2011 | type 2 diabetes mellitus | Janssen Research & Development, LLC | Completed | No outcome recorded |
| Phase 3 | NCT00975533 Comparator | Oct 2009 → Jul 2011 | type 2 diabetes mellitus | Chinese University of Hong Kong | Unknown | No outcome recorded |
| Phase 3 | NCT00757588 Comparator | Nov 2008 → Apr 2010 | type 2 diabetes mellitus | AstraZeneca | Completed | No outcome recorded |
| Phase 3 | NCT00668850 Comparator | Apr 2008 → Aug 2011 | diabetes mellitus | Generex Biotechnology Corp. | Unknown | No outcome recorded |
| Phase 3 | NCT00849576 Comparator | Apr → Aug 2008 | type 2 diabetes mellitus | Biodel | Completed | No outcome recorded |
| Phase 3 | NCT00479258 Comparator | Oct 2007 | type 1 diabetes mellitus | Pfizer | Terminated | No outcome recorded |
| Phase 3 | NCT00474045 Comparator | May 2007 → Aug 2010 | type 1 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 3 | NCT00427154 Comparator | Jan 2007 → Mar 2008 | type 2 diabetes mellitus | Novo Nordisk A/S | Terminated | No outcome recorded |
| Phase 3 | NCT00542633 Comparator | Dec 2006 → Aug 2008 | type 2 diabetes mellitus | Biodel | Completed | No outcome recorded |
| Phase 3 | NCT00348712 Comparator | Oct 2006 → Mar 2008 | type 2 diabetes mellitus | Novo Nordisk A/S | Terminated | No outcome recorded |
| Phase 3 | NCT00542724 Comparator | Sep 2006 → Jul 2008 | type 1 diabetes mellitus | Biodel | Completed | No outcome recorded |
| Phase 3 | NCT00330473 Comparator | Jun 2006 → May 2008 | type 2 diabetes mellitus | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 3 | NCT00286429 Comparator | Feb 2006 → May 2007 | type 2 diabetes mellitus | Takeda | Completed | No outcome recorded |
| Phase 3 | NCT00349427 Background | Oct 2005 → ? | type 2 diabetes mellitus | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT00157339 Comparator | Aug 2005 → May 2008 | asthma, chronic obstructive pulmonary disease, diabetes mellitus | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 3 | NCT00127634 Comparator | Jul 2005 → May 2008 | type 1 diabetes mellitus | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 3 | NCT00115570 Background | Apr 2005 → Nov 2006 | type 1 diabetes mellitus | Sanofi | Completed | No outcome recorded |
| Phase 3 | NCT00174668 Comparator | Nov 2004 → Nov 2007 | type 2 diabetes mellitus | Sanofi | Completed | No outcome recorded |
| Phase 3 | NCT00242372 Background | Aug 2004 → Mar 2006 | type 2 diabetes mellitus | AstraZeneca | Terminated | No outcome recorded |
| Phase 3 | NCT00762190 Comparator | Nov 2003 → Dec 2004 | type 2 diabetes mellitus | Takeda | Terminated | No outcome recorded |
| Phase 3 | NCT00138671 Comparator | Jan 2003 → Sep 2008 | chronic obstructive pulmonary disease, diabetes mellitus | Pfizer | Terminated | No outcome recorded |
| Phase 3 | NCT00139659 Comparator | Jan 2003 → Oct 2008 | asthma, diabetes mellitus | Pfizer | Completed | No outcome recorded |
| Phase 3 | NCT00136916 Comparator | Jun 2002 → Dec 2008 | type 2 diabetes mellitus | Pfizer | Terminated | No outcome recorded |
| Phase 3 | NCT00662714 Comparator | Sep 2001 → Dec 2011 | cystic fibrosis, diabetes mellitus | Mukoviszidose Institut gGmbH | Completed | No outcome recorded |
| Phase 3 | NCT03220425 Comparator | Feb → Nov 2001 | type 1 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 3 | NCT01520818 Comparator | Mar 2000 → Apr 2001 | type 1 diabetes mellitus, type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 3 | NCT00000620 Background | Sep 1999 → Jun 2009 | atherosclerosis, coronary artery disorder, hyperlipoproteinemia, hypertensive disorder +1 | National Heart, Lung, and Blood Institute (NHLBI) | Completed | No outcome recorded |
| Phase 3 | NCT01467323 Comparator | Apr → Sep 1998 | type 1 diabetes mellitus, type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 3 | NCT00375388 Background | Jan 1998 → Oct 2002 | type 2 diabetes mellitus | Bethesda General Hospital, Hoogeveen | Completed | No outcome recorded |
| Phase 489 trials | ||||||
| Phase 4 | NCT07494084 Comparator | Jul 2026 → Mar 2029 expected | circadian rhythm sleep disorder, shift work type | Washington State University | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07561398 Comparator | Mar → Sep 2026 expected | corneal disorder | Al-Shifa Trust Eye Hospital | Recruiting | No outcome recorded |
| Phase 4 | NCT07293715 Background | Feb 2026 → Jun 2027 expected | type 1 diabetes mellitus | Ohio State University | Recruiting | No outcome recorded |
| Phase 4 | NCT06956846 Comparator | Apr → Jun 2025 overdue | corneal disorder | Hotel Dieu de France Hospital | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT06781775 Comparator | Dec 2024 → May 2026 overdue | gestational diabetes | University of Virginia | Recruiting | No outcome recorded |
| Phase 4 | NCT06624956 Comparator | Sep 2024 → Sep 2025 | hyperglycemia | University of Washington | Completed | No outcome recorded |
| Phase 4 | NCT06145360 Comparator | Dec 2023 → Mar 2024 | type 2 diabetes mellitus | SINA Health Education and Welfare Trust | Completed | No outcome recorded |
| Phase 4 | NCT05922033 Background | Oct 2023 → Mar 2025 | gestational diabetes | Ohio State University | Completed | No outcome recorded |
| Phase 4 | NCT05768191 Comparator | Jun 2023 → Apr 2024 | type 1 diabetes mellitus | Nazi Boni University | Completed | No outcome recorded |
| Phase 4 | NCT05479214 Background | Jul 2022 → Jan 2023 | gestational diabetes | Cairo University | Completed | No outcome recorded |
| Phase 4 | NCT03527537 Comparator | May 2021 → Jun 2026 overdue | gestational diabetes | Medical College of Wisconsin | Active not recruiting | No outcome recorded |
| Phase 4 | NCT04783376 Comparator | Apr → Nov 2021 | type 1 diabetes mellitus | Sohag University | Completed | No outcome recorded |
| Phase 4 | NCT04834362 Comparator | Apr → Jun 2021 | hyperglycemia, stroke disorder | National Institute of Neurosciences and Hospital, Dhaka | Completed | No outcome recorded |
| Phase 4 | NCT06855615 Comparator | Oct 2020 → Jan 2021 | type 2 diabetes mellitus | Hospital Sultanah Aminah Johor Bahru | Completed | No outcome recorded |
| Phase 4 | NCT04385589 Comparator | May → Dec 2020 | heart failure | Assiut University | Completed | No outcome recorded |
| Phase 4 | NCT05709938 Background | Nov 2019 → Jan 2021 | — | King Edward Medical University | Completed | No outcome recorded |
| Phase 4 | NCT03982238 Comparator | Jun → Nov 2019 | type 2 diabetes mellitus | Majianhua | Completed | No outcome recorded |
| Phase 4 | NCT03928340 Background | Apr 2019 → Mar 2020 | type 1 diabetes mellitus | Kasr El Aini Hospital | Completed | No outcome recorded |
| Phase 4 | NCT04664764 Comparator | Feb 2019 → Feb 2021 | type 1 diabetes mellitus | Ain Shams University | Unknown | No outcome recorded |
| Phase 4 | NCT04690309 Comparator | Jul 2018 → Dec 2020 | type 5 diabetes mellitus | Polish Society of Diabetology | Unknown | No outcome recorded |
| Phase 4 | NCT03029702 Comparator | Feb 2018 → Aug 2023 | gestational diabetes | Maisa N. Feghali, MD | Completed | No outcome recorded |
| Phase 4 | NCT03313960 Comparator | Oct 2017 → Sep 2018 | type 2 diabetes mellitus | Informed Data Systems, Inc. | Unknown | No outcome recorded |
| Phase 4 | NCT03143816 Comparator | Sep → Dec 2017 | type 1 diabetes mellitus | University of Colorado, Denver | Completed | No outcome recorded |
| Phase 4 | NCT03513874 Background | Aug 2017 → Dec 2020 | type 1 diabetes mellitus | Second Xiangya Hospital of Central South University | Unknown | No outcome recorded |
| Phase 4 | NCT03011008 Background | Jan 2017 → Dec 2020 | type 1 diabetes mellitus | Second Xiangya Hospital of Central South University | Unknown | No outcome recorded |
| Phase 4 | NCT02906709 Background | Oct 2016 → Aug 2018 | type 2 diabetes mellitus | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 4 | NCT02847091 Background | Jul 2016 → Nov 2017 | type 2 diabetes mellitus | Astellas Pharma Inc | Completed | No outcome recorded |
| Phase 4 | NCT02806999 Comparator | Jul 2016 → Mar 2017 | hyperglycemia | Guangdong Provincial People's Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT02765347 Background | Jun 2016 → Jan 2018 | type 1 diabetes mellitus | Third Affiliated Hospital, Sun Yat-Sen University | Completed | No outcome recorded |
| Phase 4 | NCT05752929 Comparator | Jan 2016 → Dec 2018 | hyperglycemia, type 2 diabetes mellitus | Hospital Universitario Clinica San Rafael | Completed | No outcome recorded |
| Phase 4 | NCT02443402 Background | Jan → Dec 2016 | coronary artery disorder | Emory University | Completed | No outcome recorded |
| Phase 4 | NCT02556918 Background | Jan 2016 → Nov 2018 | hyperglycemia | Emory University | Completed | No outcome recorded |
| Phase 4 | NCT02967211 Comparator | Dec 2015 → Oct 2017 | type 2 diabetes mellitus | Sanofi | Completed | No outcome recorded |
| Phase 4 | NCT02967224 Comparator | Nov 2015 → Oct 2017 | type 2 diabetes mellitus | Sanofi | Completed | No outcome recorded |
| Phase 4 | NCT02429258 Background | May → Oct 2015 | type 2 diabetes mellitus | AstraZeneca | Completed | No outcome recorded |
| Phase 4 | NCT02407899 Background | Mar 2015 → Dec 2020 | type 1 diabetes mellitus | Second Xiangya Hospital of Central South University | Completed | No outcome recorded |
| Phase 4 | NCT02622113 Background | Dec 2014 → Apr 2016 | type 2 diabetes mellitus | Tanabe Pharma Corporation | Completed | No outcome recorded |
| Phase 4 | NCT02307695 Background | Nov 2014 → Mar 2017 | type 1 diabetes mellitus | Nanjing Medical University | Unknown | No outcome recorded |
| Phase 4 | NCT02220920 Background | Aug 2014 → Jul 2015 | type 2 diabetes mellitus | Tanabe Pharma Corporation | Completed | No outcome recorded |
| Phase 4 | NCT02201004 Background | Jun 2014 → Jan 2016 | type 2 diabetes mellitus | Sanofi | Completed | No outcome recorded |
| Phase 4 | NCT02176681 Comparator | Jun 2014 → Oct 2017 | — | University Hospital, Strasbourg, France | Completed | No outcome recorded |
| Phase 4 | NCT02081599 Background | Jan 2014 → Jan 2016 | type 2 diabetes mellitus | Tanabe Pharma Corporation | Completed | No outcome recorded |
| Phase 4 | NCT02451917 Comparator | Dec 2013 → Aug 2016 | chronic kidney disease, type 2 diabetes mellitus | University of Sao Paulo General Hospital | Completed | No outcome recorded |
| Phase 4 | NCT02002221 Background | Dec 2013 → Feb 2015 | type 2 diabetes mellitus | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 4 | NCT02758522 Comparator | Oct 2013 → Oct 2015 | diabetes mellitus, hyperglycemia | Hospital Universitario Dr. Jose E. Gonzalez | Completed | No outcome recorded |
| Phase 4 | NCT01971047 Comparator | Oct 2013 → Sep 2018 | type 1 diabetes mellitus, type 2 diabetes mellitus | Emory University | Withdrawn | No outcome recorded |
| Phase 4 | NCT01862263 Background | May 2013 → Jul 2015 | type 2 diabetes mellitus | Novartis Pharmaceuticals | Terminated | No outcome recorded |
| Phase 4 | NCT02216799 Comparator | Mar 2013 → Aug 2015 | — | King Faisal Specialist Hospital & Research Center | Completed | No outcome recorded |
| Phase 4 | NCT01683331 Comparator | Aug 2012 → Feb 2018 | — | University of Michigan | Completed | No outcome recorded |
| Phase 4 | NCT01649466 Comparator | Aug 2012 → Oct 2013 | type 2 diabetes mellitus | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 4 | NCT01592279 Comparator | Jun 2012 → Jun 2014 | — | Hadassah Medical Organization | Unknown | No outcome recorded |
| Phase 4 | NCT01341717 Background | Feb 2012 → May 2014 | type 2 diabetes mellitus | Jothydev's Diabetes and Research Centre | Completed | No outcome recorded |
| Phase 4 | NCT01468519 Comparator | Jan 2012 → Sep 2014 | erectile dysfunction, type 2 diabetes mellitus | Jothydev's Diabetes and Research Centre | Completed | No outcome recorded |
| Phase 4 | NCT01417897 Comparator | Sep 2011 → May 2012 | type 2 diabetes mellitus | ikfe-CRO GmbH | Unknown | No outcome recorded |
| Phase 4 | NCT01269996 Comparator | May 2011 → Jul 2014 | type 2 diabetes mellitus | Chinese University of Hong Kong | Completed | No outcome recorded |
| Phase 4 | NCT01131052 Comparator | Mar 2011 → Dec 2013 | hyperglycemia, type 2 diabetes mellitus | Guillermo Umpierrez | Completed | No outcome recorded |
| Phase 4 | NCT01143948 Comparator | Jan → Apr 2011 | cirrhosis of liver, type 2 diabetes mellitus | Cairo University | Unknown | No outcome recorded |
| Phase 4 | NCT01504620 Background | Jan → Apr 2011 | diabetes mellitus | IKFE Institute for Clinical Research and Development | Completed | No outcome recorded |
| Phase 4 | NCT01270191 Comparator | Nov 2010 → Dec 2014 | type 2 diabetes mellitus | Taipei Veterans General Hospital, Taiwan | Unknown | No outcome recorded |
| Phase 4 | NCT01235819 Comparator | Nov 2010 → Sep 2011 | type 1 diabetes mellitus | Command Hospital, India | Completed | No outcome recorded |
| Phase 4 | NCT01122979 Comparator | Jul 2010 → Oct 2013 | type 2 diabetes mellitus | Sanofi | Completed | No outcome recorded |
| Phase 4 | NCT02607410 Comparator | Jan 2010 → Jan 2012 | type 2 diabetes mellitus | University of Sao Paulo General Hospital | Completed | No outcome recorded |
| Phase 4 | NCT00979628 Comparator | Jan 2010 → Mar 2012 | hyperglycemia, type 2 diabetes mellitus | Guillermo Umpierrez, MD | Completed | No outcome recorded |
| Phase 4 | NCT00985712 Background | Oct 2009 → Jul 2011 | type 1 diabetes mellitus | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 4 | NCT01269047 Comparator | Aug 2009 → Aug 2016 | type 1 diabetes mellitus | Albert Einstein College of Medicine | Completed | No outcome recorded |
| Phase 4 | NCT00949442 Comparator | Jul 2009 → Jul 2012 | type 2 diabetes mellitus | Sanofi | Completed | No outcome recorded |
| Phase 4 | NCT02278913 Comparator | Apr 2009 → Apr 2010 | diabetes mellitus, hyperglycemia | Universidad Nacional de Asunción | Completed | No outcome recorded |
| Phase 4 | NCT01013402 Background | Dec 2008 → Apr 2009 | hypoglycemia | Gulhane School of Medicine | Completed | No outcome recorded |
| Phase 4 | NCT01150617 Comparator | Dec 2008 → Nov 2010 | peripheral vascular disease, type 2 diabetes mellitus | IRCCS San Raffaele | Terminated | No outcome recorded |
| Phase 4 | NCT00941148 Comparator | Apr 2008 → Mar 2009 | diabetes mellitus, noninsulin-dependent, 2 | ikfe-CRO GmbH | Completed | No outcome recorded |
| Phase 4 | NCT00590044 Comparator | Dec 2007 → Jun 2008 | diabetic ketoacidosis | Emory University | Completed | No outcome recorded |
| Phase 4 | NCT00596687 Comparator | Dec 2007 → Dec 2009 | hyperglycemia, type 2 diabetes mellitus | Emory University | Completed | No outcome recorded |
| Phase 4 | NCT00523393 Comparator | Aug 2007 → Dec 2009 | type 2 diabetes mellitus | Heidelberg University | Unknown | No outcome recorded |
| Phase 4 | NCT00747279 Comparator | Jun 2007 → ? | ischemic stroke | Hospital Sao Domingos | Unknown | No outcome recorded |
| Phase 4 | NCT00346996 Comparator | May 2007 → Nov 2011 | type 1 diabetes mellitus | Lise Tarnow | Completed | No outcome recorded |
| Phase 4 | NCT00442767 Comparator | Feb 2007 → Feb 2009 | type 1 diabetes mellitus | Montefiore Medical Center | Completed | No outcome recorded |
| Phase 4 | NCT00841919 Comparator | Dec 2006 → Mar 2009 | type 2 diabetes mellitus | Cook County Health | Completed | No outcome recorded |
| Phase 4 | NCT00391027 Comparator | Dec 2006 → Aug 2008 | type 2 diabetes mellitus | Pfizer | Completed | No outcome recorded |
| Phase 4 | NCT00590226 Comparator | Dec 2006 → Jan 2008 | type 2 diabetes mellitus | Emory University | Completed | No outcome recorded |
| Phase 4 | NCT00859079 Comparator | Jun → Dec 2006 | hyperglycemia, type 2 diabetes mellitus | Medical University of Graz | Completed | No outcome recorded |
| Phase 4 | NCT01240785 Comparator | Jun 2006 → Jan 2011 | gestational diabetes | Turku University Hospital | Completed | No outcome recorded |
| Phase 4 | NCT00362778 Comparator | Jan → Dec 2006 | acute myocardial infarction, diabetes mellitus, hyperglycemia | Hospital Clinic of Barcelona | Completed | No outcome recorded |
| Phase 4 | NCT00394407 Comparator | Sep 2005 → Jun 2006 | hyperglycemia, type 2 diabetes mellitus | Emory University | Completed | No outcome recorded |
| Phase 4 | NCT01271517 Comparator | Sep 2005 → Mar 2011 | type 1 diabetes mellitus | Karolinska Institutet | Unknown | No outcome recorded |
| Phase 4 | NCT00177398 Background | Feb 2005 → Aug 2006 | hyperglycemia, type 2 diabetes mellitus | University of Pittsburgh | Completed | No outcome recorded |
| Phase 4 | NCT00747409 Comparator | Jul 2004 → Mar 2009 | type 2 diabetes mellitus | Munich Municipal Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT00160485 Comparator | Jun 2004 → Jun 2009 | gestational diabetes | Tripler Army Medical Center | Withdrawn | No outcome recorded |
| Phase 4 | NCT00686712 Comparator | Feb 2003 → Aug 2009 | type 2 diabetes mellitus | Charles Drew University of Medicine and Science | Completed | No outcome recorded |
| Phase 4 | NCT02154347 Background | ? → Jul 2016 | type 2 diabetes mellitus | Kissei Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase not applicable73 trials | ||||||
| — | NCT07540975 Comparator | May 2026 → Dec 2029 expected | hyperglycemia | Dae Wook Hwang | Not yet recruiting | No outcome recorded |
| — | NCT07460336 Background | May 2026 → Dec 2027 expected | latent autoimmune diabetes in adults | Second Xiangya Hospital of Central South University | Not yet recruiting | No outcome recorded |
| — | NCT07423637 Comparator | Apr 2026 → Sep 2027 expected | type 1 diabetes mellitus | Helsinki University Central Hospital | Not yet recruiting | No outcome recorded |
| — | NCT07383415 Comparator | Mar → Dec 2026 expected | anosmia | Amin Javer | Not yet recruiting | No outcome recorded |
| — | NCT07451561 Comparator | Mar 2026 → Mar 2027 expected | — | Sohag University | Not yet recruiting | No outcome recorded |
| — | NCT07074379 Background | Jul 2025 → Aug 2027 expected | chronic pancreatitis | Changhai Hospital | Recruiting | No outcome recorded |
| — | NCT07007130 Comparator | Jun 2025 → Mar 2026 overdue | — | Ain Shams University | Not yet recruiting | No outcome recorded |
| — | NCT06487598 Comparator | Jul 2024 → Jul 2025 overdue | type 1 diabetes mellitus | Hirabai Cowasji Jehangir Medical Research Institute | Active not recruiting | No outcome recorded |
| — | NCT05600075 Comparator | Feb → Sep 2023 | mixed dermis disorder | Zagazig University | Unknown | No outcome recorded |
| — | NCT04918407 Background | Jan 2022 → Jul 2025 | — | Shahid Beheshti University of Medical Sciences | Completed | No outcome recorded |
| — | NCT05010356 Background | Aug 2021 → Dec 2022 overdue | breast cancer, metabolic disease | University of Copenhagen | Recruiting | No outcome recorded |
| — | NCT04876079 Comparator | Jun 2021 → Jun 2023 | type 1 diabetes mellitus | Montreal Clinical Research Institute | Completed | No outcome recorded |
| — | NCT04781777 Comparator | Mar → May 2021 | — | Minia University | Unknown | No outcome recorded |
| — | NCT04781751 Comparator | Feb → Apr 2021 | neuropathy, painful | Minia University | Unknown | No outcome recorded |
| — | NCT04137328 Comparator | Nov 2019 → Nov 2022 | diabetic polyneuropathy | Fudan University | Unknown | No outcome recorded |
| — | NCT03929419 Comparator | Apr 2019 → Mar 2021 | — | University Hospital Tuebingen | Completed | No outcome recorded |
| — | NCT03915054 Comparator | Apr → Dec 2019 | polycystic ovary syndrome | My Duc Hospital | Completed | No outcome recorded |
| — | NCT03651661 Comparator | Jul → Nov 2018 | obesity disorder | University Hospital Tuebingen | Completed | No outcome recorded |
| — | NCT03349489 Comparator | May 2018 → Jan 2019 | type 1 diabetes mellitus | McGill University Health Centre/Research Institute of the McGill University Health Centre | Unknown | No outcome recorded |
| — | NCT04907838 Background | May 2018 → Jul 2021 | type 2 diabetes mellitus | University of Southern Denmark | Unknown | No outcome recorded |
| — | NCT03632681 Comparator | Apr 2018 → Apr 2019 | obesity disorder | University of Birmingham | Completed | No outcome recorded |
| — | NCT03740581 Comparator | Nov 2017 → Jun 2019 | ulcer of lower limbs | Post Graduate Institute of Medical Education and Research, Chandigarh | Unknown | No outcome recorded |
| — | NCT03273881 Comparator | Oct 2017 → Dec 2023 | diabetes mellitus, obstetric disorder | HaEmek Medical Center, Israel | Unknown | No outcome recorded |
| — | NCT04554615 Comparator | Sep 2017 → Mar 2018 | hyperglycemia | Tanta University | Completed | No outcome recorded |
| — | NCT03394131 Comparator | Jul 2017 → May 2018 | carpal tunnel syndrome | Assiut University | Unknown | No outcome recorded |
| — | NCT02879409 Background | Nov 2016 → Oct 2023 overdue | type 2 diabetes mellitus | Weill Cornell Medical College in Qatar | Active not recruiting | No outcome recorded |
| — | NCT02930044 Background | Oct 2016 → Nov 2021 | diabetic ketoacidosis | University of Maryland, Baltimore | Completed | No outcome recorded |
| — | NCT02870361 Comparator | Aug 2016 → Feb 2018 | acute insulin response | University Hospital Tuebingen | Completed | No outcome recorded |
| — | NCT02956655 Comparator | Jul 2016 → Jul 2017 | type 2 diabetes mellitus | First Affiliated Hospital, Sun Yat-Sen University | Unknown | No outcome recorded |
| — | NCT02622854 Comparator | Jun 2016 → Aug 2020 | acute pancreatitis | University Medical Centre Ljubljana | Completed | No outcome recorded |
| — | NCT02933645 Comparator | Apr → Dec 2016 | — | Turku University Hospital | Completed | No outcome recorded |
| — | NCT04726657 Comparator | Jan 2016 → Feb 2020 | type 2 diabetes mellitus | Aristotle University Of Thessaloniki | Completed | No outcome recorded |
| — | NCT02548494 Background | Nov 2015 → Feb 2019 | diabetic ketoacidosis, type 1 diabetes mellitus | Chattanooga-Hamilton County Hospital Authority | Terminated | No outcome recorded |
| — | NCT02468999 Comparator | Jan → Dec 2015 | — | University Hospital Tuebingen | Completed | No outcome recorded |
| — | NCT02234440 Comparator | Sep 2014 → Dec 2015 | cirrhosis of liver | Institute of Liver and Biliary Sciences, India | Completed | No outcome recorded |
| — | NCT02359617 Background | Feb 2013 → Oct 2014 | type 1 diabetes mellitus | Medical University of Graz | Completed | No outcome recorded |
| — | NCT01797601 Comparator | Feb 2013 → Apr 2014 | diabetes mellitus, obesity disorder | University Hospital Tuebingen | Completed | No outcome recorded |
| — | NCT02006342 Background | Nov 2012 → Apr 2013 | diabetic ketoacidosis | The University of Texas Health Science Center, Houston | Completed | No outcome recorded |
| — | NCT01833559 Background | Jun 2012 → May 2021 | gestational diabetes | First Affiliated Hospital, Sun Yat-Sen University | Unknown | No outcome recorded |
| — | NCT01392898 Comparator | Feb 2012 → May 2014 | type 2 diabetes mellitus | Radboud University Medical Center | Unknown | No outcome recorded |
| — | NCT02205996 Comparator | Nov 2011 → May 2013 | type 2 diabetes mellitus | University of Hull | Completed | No outcome recorded |
| — | NCT01424046 Comparator | May 2011 → Jun 2014 | type 1 diabetes mellitus | University of Pittsburgh | Completed | No outcome recorded |
| — | NCT03179280 Comparator | Mar → May 2011 | type 1 diabetes mellitus | Aristotle University Of Thessaloniki | Completed | No outcome recorded |
| — | NCT01804413 Comparator | Mar 2011 → Nov 2013 | pituitary deficiency | Oregon Health and Science University | Unknown | No outcome recorded |
| — | NCT01244178 Comparator | Nov 2010 → Dec 2013 | infectious disease with sepsis | peter metrakos | Unknown | No outcome recorded |
| — | NCT01855243 Comparator | Mar 2010 → Feb 2014 | type 2 diabetes mellitus | Cairo University | Completed | No outcome recorded |
| — | NCT01016509 Comparator | Dec 2009 → Jun 2010 | coronary restenosis | University of Campania Luigi Vanvitelli | Completed | No outcome recorded |
| — | NCT02305069 Background | Oct 2009 → Oct 2011 | muscular atrophy, obesity disorder | University of Nottingham | Completed | No outcome recorded |
| — | NCT00899483 Comparator | Jul 2009 → Jul 2012 | type 2 diabetes mellitus | University Hospital Birmingham | Unknown | No outcome recorded |
| — | NCT01140438 Comparator | Mar 2009 → Nov 2018 | diabetes mellitus | Norwegian University of Science and Technology | Completed | No outcome recorded |
| — | NCT01225159 Comparator | Sep 2008 → Mar 2009 | hypoglycemia, nosocomial infection | Prince of Songkla University | Terminated | No outcome recorded |
| — | NCT00653510 Background | Mar 2008 → Nov 2010 | type 2 diabetes mellitus | University of Aarhus | Completed | No outcome recorded |
| — | NCT00858273 Comparator | Mar 2008 → Mar 2011 | type 1 diabetes mellitus | Nemours Children's Clinic | Completed | No outcome recorded |
| — | NCT00638209 Comparator | Feb 2008 → May 2010 | — | University Hospital Tuebingen | Unknown | No outcome recorded |
| — | NCT00764712 Comparator | Feb → Apr 2008 | hyperglycemia | Charles University, Czech Republic | Completed | No outcome recorded |
| — | NCT00679237 Comparator | Sep 2007 → Dec 2019 | coronary artery disorder | Sorlandet Hospital HF | Completed | No outcome recorded |
| — | NCT00609986 Comparator | Jul 2007 → Oct 2010 | diabetes mellitus, hyperglycemia | Medical University of South Carolina | Completed | No outcome recorded |
| — | NCT00858897 Background | Jun 2007 → Feb 2008 | type 1 diabetes mellitus | Nemours Children's Clinic | Completed | No outcome recorded |
| — | NCT00984737 Background | May 2007 → Nov 2008 | diabetes mellitus, hyperglycemia, myocardial ischemia | Baskent University | Completed | No outcome recorded |
| — | NCT00582036 Comparator | Feb 2007 → May 2009 | hyperglycemia | University of Oklahoma | Terminated | No outcome recorded |
| — | NCT00995501 Comparator | Jan 2007 → Dec 2015 | — | d sessler | Terminated | No outcome recorded |
| — | NCT00287456 Background | Feb 2006 | cystic fibrosis-related diabetes | University of Texas Southwestern Medical Center | Withdrawn | No outcome recorded |
| — | NCT00264641 Background | Jan 2006 → Feb 2008 | cognitive disorder, hypoglycemia | Hypoglycaemia Research Group | Completed | No outcome recorded |
| — | NCT00137254 Comparator | Dec 2005 → Feb 2007 | — | United States Army Institute of Surgical Research | Completed | No outcome recorded |
| — | NCT00506194 Background | Oct 2005 → Aug 2007 | type 2 diabetes mellitus | Taipei Veterans General Hospital, Taiwan | Completed | No outcome recorded |
| — | NCT00159211 Comparator | May 2005 → May 2007 | type 2 diabetes mellitus | Assistance Publique - Hôpitaux de Paris | Terminated | No outcome recorded |
| — | NCT00927524 Comparator | Apr 2005 → Apr 2006 | type 1 diabetes mellitus | Vanderbilt University | Completed | No outcome recorded |
| — | NCT00574405 Comparator | Apr 2005 → Mar 2010 | type 1 diabetes mellitus | Arkansas Children's Hospital Research Institute | Completed | No outcome recorded |
| — | NCT00920725 Comparator | Jan 2005 → Jul 2007 | diabetic ketoacidosis | Rush University Medical Center | Completed | No outcome recorded |
| — | NCT00147836 Comparator | Sep 2004 → Oct 2007 | type 2 diabetes mellitus | Sun Yat-sen University | Completed | No outcome recorded |
| — | NCT00232583 Comparator | Nov 2003 → Dec 2011 | type 2 diabetes mellitus | University of Texas Southwestern Medical Center | Completed | No outcome recorded |
| — | NCT00005889 Background | Oct 1999 → ? | hyperglycemia | National Center for Research Resources (NCRR) | Unknown | No outcome recorded |
| — | NCT00431665 Background | Jul 1999 → Jun 2000 | — | Medical University of Vienna | Completed | No outcome recorded |
Press releases naming this drug 71 releases
| Date | Issuer | Release |
|---|---|---|
| 2026-03-26 | Novo Nordisk A/S | Novo Nordisk A/S: Awiqli® approved in the US, the first and only once-weekly basal insulin treatment for adults with type 2 diabetes novonordisk.com ↗ |
| 2024-07-10 | Novo Nordisk A/S | Novo Nordisk receives Complete Response Letter in the US for once-weekly basal insulin icodec novonordisk.com ↗ |
| 2024-03-21 | Novo Nordisk A/S | Awiqli® (once-weekly basal insulin icodec) recommended for approval for the treatment of diabetes by the European regulatory authorities novonordisk.com ↗ |
| 2024-01-08 | Novo Nordisk A/S | COMBINE 3 phase 3a trial successfully completed with once-weekly IcoSema demonstrating non-inferior reduction in HbA1c versus daily basal-bolus treatment (insulin glargine U100 and insulin aspart) in people with type 2 diabetes novonordisk.com ↗ |
| 2023-03-16 | Sanofi | Press Release: Sanofi cuts U.S. list price of Lantus®, its most-prescribed insulin, by 78% and caps out-of-pocket Lantus costs at $35 for all patients with commercial insurance sanofi.com ↗ |
| 2022-10-03 | Novo Nordisk A/S | Once-weekly insulin icodec demonstrates superior reduction in HbA1c in combination with a dosing guide app versus once-daily basal insulin in people with type 2 diabetes in ONWARDS 5 phase 3a trial novonordisk.com ↗ |
| 2022-07-29 | Novo Nordisk A/S | Novo Nordisk achieves primary objectives of ONWARDS 3 and 4 trials with once-weekly insulin icodec demonstrating superior reduction in HbA1c vs insulin degludec in ONWARDS 3 novonordisk.com ↗ |
| 2022-06-03 | Novo Nordisk A/S | Novo Nordisk achieves primary objectives of ONWARDS 1 and 6 trials with once-weekly insulin icodec demonstrating superior reduction in HbA1c vs insulin glargine U100 in ONWARDS 1 novonordisk.com ↗ |
| 2022-04-28 | Novo Nordisk A/S | Once-weekly insulin icodec demonstrates superior reduction in HbA1c vs insulin degludec in people with type 2 diabetes in ONWARDS 2 phase 3a trial novonordisk.com ↗ |
| 2021-11-26 | Novo Nordisk A/S | Novo Nordisk announces impact from Volume Based Procurement for insulin in China novonordisk.com ↗ |
| 2021-06-28 | Sanofi | Media Update: New Soliqua®* data shows improved blood sugar control without weight gain versus premixed insulin sanofi.com ↗ |
| 2019-02-20 | Novo Nordisk A/S | Abbott and Novo Nordisk enter partnership to provide integrated digital solution to people with diabetes using insulin novonordisk.com ↗ |
| 2018-12-19 | Novartis Pharmaceuticals | Sandoz enters into commercialization and supply agreement for insulin biosimilars, anticipating growing demand as diabetes burden rises novartis.com ↗ |
| 2018-10-26 | Novo Nordisk A/S | Oral semaglutide demonstrates statistically significant reductions in HbA1c and body weight in people with long duration of type 2 diabetes treated with insulin novonordisk.com ↗ |
| 2017-09-29 | Novo Nordisk A/S | Novo Nordisk's new fast-acting mealtime insulin Fiasp® approved in the US novonordisk.com ↗ |
| 2017-03-29 | Novo Nordisk A/S | Novo Nordisk genindsender registreringsansøgningen for hurtigtvirkende insulin aspart i USA novonordisk.com ↗ |
| 2017-03-29 | Novo Nordisk A/S | Novo Nordisk resubmits new drug application for fast-acting insulin aspart in the US novonordisk.com ↗ |
| 2017-01-10 | Novo Nordisk A/S | Fiasp® (hurtigtvirkende insulin aspart) godkendt i Europa novonordisk.com ↗ |
| 2017-01-10 | Novo Nordisk A/S | Fiasp® (fast-acting insulin aspart) approved in Europe novonordisk.com ↗ |
| 2016-11-29 | Novo Nordisk A/S | Novo Nordisk A/S: Tresiba® demonstrates a safe cardiovascular profile and reduces the risk of severe hypoglycaemia compared to insulin glargine U100 in the DEVOTE trial novonordisk.com ↗ |
| 2016-11-29 | Novo Nordisk A/S | Novo Nordisk A/S: Tresiba® viser en sikker kardiovaskulær profil og reducerer risikoen for alvorlig hypoglykæmi sammenlignet med insulin glargin U100 i DEVOTE-studiet novonordisk.com ↗ |
| 2016-11-11 | Novo Nordisk A/S | Novo Nordisk receives positive opinion from the European regulatory authorities for Fiasp® (fast-acting insulin aspart) for the treatment of diabetes novonordisk.com ↗ |
| 2016-11-11 | Novo Nordisk A/S | Novo Nordisk får positiv udtalelse fra de europæiske lægemiddelmyndigheder om Fiasp® (hurtigtvirkende insulin aspart) til behandling af diabetes novonordisk.com ↗ |
| 2016-10-07 | Novo Nordisk A/S | Novo Nordisk modtager Complete Response Letter i USA vedrørende hurtigerevirkende insulin aspart novonordisk.com ↗ |
| 2016-10-07 | Novo Nordisk A/S | Novo Nordisk receives Complete Response Letter in the US for faster-acting insulin aspart novonordisk.com ↗ |
| 2016-05-20 | Novo Nordisk A/S | FDA offentliggør briefingmateriale forud for møde i rådgivende komite om IDegLira, en kombination af insulin degludec og liraglutid novonordisk.com ↗ |
| 2016-05-20 | Novo Nordisk A/S | FDA posts briefing materials prior to Advisory Committee meeting for IDegLira, a fixed combination product of insulin degludec and liraglutide novonordisk.com ↗ |
| 2016-02-23 | Novo Nordisk A/S | Tresiba® viser signifikant lavere forekomst af hypoglykæmi end insulin glargin U100 i blindet fase 3b-studie i mennesker med type 1-diabetes novonordisk.com ↗ |
| 2016-02-23 | Novo Nordisk A/S | Tresiba® demonstrates significantly lower rate of hypoglycaemia than insulin glargine U100 in blinded phase 3b trial in people with type 1 diabetes novonordisk.com ↗ |
| 2016-01-29 | Novo Nordisk A/S | Tresiba® viser signifikant lavere forekomst af hypoglykæmi end insulin glargin i blindet fase 3b-studie i mennesker med type 2-diabetes novonordisk.com ↗ |
| 2016-01-29 | Novo Nordisk A/S | Tresiba® demonstrates significantly lower rate of hypoglycaemia than insulin glargine in blinded phase 3b trial in people with type 2 diabetes novonordisk.com ↗ |
| 2015-12-09 | Novo Nordisk A/S | Novo Nordisk indsender registreringsansøgning for hurtigerevirkende insulin aspart i USA til behandling af type 1- og type 2-diabetes novonordisk.com ↗ |
| 2015-12-09 | Novo Nordisk A/S | Novo Nordisk files for regulatory approval of faster-acting insulin aspart in the US for the treatment of type 1 and 2 diabetes novonordisk.com ↗ |
| 2015-12-04 | Novo Nordisk A/S | Novo Nordisk indsender registreringsansøgning for hurtigerevirkende insulin aspart i EU til behandling af type 1- og type 2-diabetes novonordisk.com ↗ |
| 2015-12-04 | Novo Nordisk A/S | Novo Nordisk files for regulatory approval of faster-acting insulin aspart in the EU for the treatment of type 1 and 2 diabetes novonordisk.com ↗ |
| 2015-08-24 | Novo Nordisk A/S | Novo Nordisk afslutter andet og sidste fase 3a-studie med liraglutid som tillægsbehandling til insulin ved behandling af type 1-diabetes (NN9211) novonordisk.com ↗ |
| 2015-08-24 | Novo Nordisk A/S | Novo Nordisk completes second and final phase 3a trial with liraglutide as adjunct therapy to insulin for people with type 1 diabetes (NN9211) novonordisk.com ↗ |
| 2015-03-25 | Novo Nordisk A/S | Novo Nordisk A/S : Novo Nordisk afslutter fase 3a-studier, der sammenligner hurtigerevirkende insulin aspart med NovoRapid® i type 1- og type 2-diabetes novonordisk.com ↗ |
| 2015-03-25 | Novo Nordisk A/S | Novo Nordisk A/S: Novo Nordisk completes phase 3a trials comparing faster-acting insulin aspart with NovoRapid® in people with type 1 and type 2 diabetes novonordisk.com ↗ |
| 2013-01-21 | Novo Nordisk A/S | Tresiba® (insulin degludec) og Ryzodeg® (insulin degludec/insulin aspart) får markedsføringstilladelse i Europa novonordisk.com ↗ |
| 2012-12-25 | Novo Nordisk A/S | Ryzodeg® (insulin degludec/insulin aspart) approved in Japan novonordisk.com ↗ |
| 2012-12-25 | Novo Nordisk A/S | Ryzodeg® (insulin degludec/insulin aspart) godkendt i Japan novonordisk.com ↗ |
| 2012-12-03 | Novo Nordisk A/S | Ryzodeg® (insulin degludec/insulin aspart) passed review by First Committee on Drugs of Pharmaceutical Affairs in Japan novonordisk.com ↗ |
| 2012-12-03 | Novo Nordisk A/S | Ryzodeg® (insulin degludec/insulin aspart) passerer evaluering i japansk medicinkomite novonordisk.com ↗ |
| 2012-11-08 | Novo Nordisk A/S | Positiv afstemning i FDA's rådgivende komite vedrørende godkendelse af insulin degludec og insulin degludec/ insulin aspart novonordisk.com ↗ |
| 2012-11-08 | Novo Nordisk A/S | Insulin degludec and insulin degludec/insulin aspart receive positive vote for approval from FDA Advisory Committee novonordisk.com ↗ |
| 2012-11-06 | Novo Nordisk A/S | FDA offentliggør briefingmateriale forud for mødet i den rådgivende komite om insulin degludec og insulin degludec/insulin aspart novonordisk.com ↗ |
| 2012-11-06 | Novo Nordisk A/S | FDA posts briefing materials prior to Advisory Committee meeting for insulin degludec and insulin degludec/insulin aspart novonordisk.com ↗ |
| 2012-10-25 | Novo Nordisk A/S | FDA offentliggør fokus for mødet i den rådgivende komite om insulin degludec og insulin degludec/insulin aspart novonordisk.com ↗ |
| 2012-10-25 | Novo Nordisk A/S | FDA discloses focus of Advisory Committee meeting on insulin degludec and insulin degludec/insulin aspart novonordisk.com ↗ |
| 2012-10-19 | Novo Nordisk A/S | Novo Nordisk modtager positive udtalelser om Tresiba® (insulin degludec) og Ryzodeg® (insulin degludec/insulin aspart) fra de europæiske registreringsmyndigheder novonordisk.com ↗ |
| 2012-10-19 | Novo Nordisk A/S | Tresiba® (insulin degludec) and Ryzodeg® (insulin degludec/insulin aspart) receive positive opinions from the European regulatory authorities novonordisk.com ↗ |
| 2012-09-28 | Novo Nordisk A/S | Novo Nordisk A/S: Tresiba® (insulin degludec) approved in Japan novonordisk.com ↗ |
| 2012-09-28 | Novo Nordisk A/S | Novo Nordisk A/S: Tresiba® (insulin degludec) godkendt i Japan novonordisk.com ↗ |
| 2012-08-31 | Novo Nordisk A/S | Novo Nordisk A/S : Insulin degludec passerer evalueringen i japansk medicinkomite novonordisk.com ↗ |
| 2012-08-31 | Novo Nordisk A/S | Novo Nordisk A/S : Insulin degludec passed the review by the First Committee on Drugs of Pharmaceutical Affairs in Japan novonordisk.com ↗ |
| 2012-07-18 | Novo Nordisk A/S | Novo Nordisk A/S: FDA berammer møde i rådgivende komite om insulin degludec og insulin degludec/insulin aspart novonordisk.com ↗ |
| 2012-07-18 | Novo Nordisk A/S | Novo Nordisk A/S: FDA schedules Advisory Committee meeting for insulin degludec and insulin degludec/insulin aspart novonordisk.com ↗ |
| 2012-06-08 | Novo Nordisk A/S | Novo Nordisk A/S: FDA forlænger registreringssprocessen for insulin degludec og insulin degludec/insulin aspart med tre måneder novonordisk.com ↗ |
| 2012-06-08 | Novo Nordisk A/S | Novo Nordisk A/S: FDA extends regulatory review period for insulin degludec and insulin degludec/insulin aspart by three months novonordisk.com ↗ |
| 2011-12-22 | Novo Nordisk A/S | Novo Nordisk files for regulatory approval of the ultra-long-acting insulin Degludec in Japan novonordisk.com ↗ |
| 2011-11-07 | Novo Nordisk A/S | Novo Nordisk A/S: DegludecPlus giver bedre blodsukkerregulering end insulin glargin i et fase 3a-studie med japanske type 2-diabetikere novonordisk.com ↗ |
| 2011-11-07 | Novo Nordisk A/S | Novo Nordisk A/S: DegludecPlus provides superior glycaemic control compared to insulin glargine in a phase 3a trial in Japanese people with type 2 diabetes novonordisk.com ↗ |
| 2010-12-22 | Novo Nordisk A/S | Degludec giver væsentligt nedsat risiko for natlig hypoglykæmi sammenlignet med insulin glargin i to langtidsstudier novonordisk.com ↗ |
| 2010-12-22 | Novo Nordisk A/S | Degludec significantly reduces risk of hypoglycaemia during the night compared to insulin glargine in two long-term studies novonordisk.com ↗ |
| 2009-06-28 | Novo Nordisk A/S | Novo Nordisk insulin analogues have proven safety profiles novonordisk.com ↗ |
| 2008-01-14 | Novo Nordisk A/S | Novo Nordisk refocuses its activities within inhaled insulin and discontinues the development of AERx® novonordisk.com ↗ |
| 2008-01-14 | Novo Nordisk A/S | Novo Nordisk omprioriterer sine aktiviteter inden for inhalerbar insulin og indstiller udviklingen af AERx® novonordisk.com ↗ |
| 2007-06-21 | Novo Nordisk A/S | Liraglutide giver en væsentligt bedre blodsukkerregulering end insulin glargine i fase 3-studie novonordisk.com ↗ |
| 2007-06-21 | Novo Nordisk A/S | Liraglutide provides significantly better glucose control than insulin glargine in phase 3 study novonordisk.com ↗ |
| 2005-06-16 | Novo Nordisk A/S | Novo Nordisk receives US approval of Levemir® and becomes the first company with a full range of insulin analogues in the US novonordisk.com ↗ |
Evidence & citations 103 cited values
Every value below carries the sentence it was read from. 711 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Insulin | “This study is designed to demonstrate that addition of rosiglitazone (4mg) to insulin in Type 2 diabetes mellitus subjects who have not achieved glycemic goals on insulin...” NCT00349427 ↗379“Insulin and pioglitazone resulted in a significant decrease in HbA1c (-1.6% and -1.2%, respectively) and a significant increase in total body fat mass (1+/-2.3 and 3.3+/-2.7...” PMID 19683825 ↗ Aug 2009 “Stable doses of antihyperglycemic agents (sulfonylurea agent, thiazolidinediones, dipeptidyl peptidase 4 \[DPP-4\] inhibitors, metformin, insulin \[all types\]) and their combinations” NCT01106651 ↗ “Oramed Pharmaceuticals tested the capacity of its oral insulin capsule (ORMD-0801, 8 mg insulin) in addressing this resistant clinical state.” PMID 23593142 ↗ Apr 2013 “Therapy cocktail of Glucose, Insulin and Potassium. The medications will be prepared as per standard protocol. Administered intravenously.” NCT05627479 ↗ “a quantity of 5 grams of gel with hydroxypropyl-beta-cyclodextrin complexed with insulin (HPβCD-I) was placed on the pressure ulcer” NCT02418676 ↗ “2 U/kg bolus of insulin (Human regular insulin) to be administered IV followed by an infusion of 2 U/ kg/min.” NCT02746432 ↗ “56 subjects will receive metabolically active insulin by subcutaneous injections for 36 months (twice daily)” NCT00654121 ↗ “traditional therapy, such as insulin injection daily, monitoring random and postprandial blood glucose.” NCT01496339 ↗ “All patients will receive the standard of care which is a protocol based continuous insulin infusion” NCT02930044 ↗ “Participants who require glycemic rescue after Glycemic Rescue 1 will receive open-label insulin.” NCT01485614 ↗ “Oocytes in AREG-TRIGGER medium will be mature in AREG + FSH + HSA + Insulin + Estradiol medium.” NCT03915054 ↗ “polypharmacy for glucose control (metformin, repaglinide/glimepiride, pioglitazone or insulin)” NCT00133718 ↗ “Patients will receive 40 IU of intranasal insulin (Humulin R) via a metered nasal dispenser” NCT02729064 ↗ “infusion of 5% glucose and insulin, to maintain blood glucose at 5-8 mmol/l” NCT02622854 ↗ “after administration of Technosphere® Insulin Inhalation Powder” NCT00757367 ↗ “Insulin was given bolusly if the blood sugar more than 250 mg%.” NCT01225159 ↗ “Intralesional insulin injection (Human actrapid insulin” NCT06230146 ↗ “applying topical insulin on the right side of the face” NCT06590909 ↗ “4 units (0.1 ml) of human soluble insulin (Actrapid)” NCT07432581 ↗ “Insulin (Novolin R) and Glutathione (INS-GSH)” NCT05266417 ↗ “weekly pulsatile insulin infusion therapy” PMID 20189608 ↗ Mar 2010 “exogenous insulin injection daily” NCT01374854 ↗ “Afrezza inhaled insulin low dose.” NCT03234491 ↗ “insulin with or without metformin” NCT02897349 ↗ “Glucose-insulin-potassium” NCT00823108 ↗ “Actrapid® (Insulin)” NCT00135473 ↗ “insulin” NCT05922033 ↗ |
| Known as | Actrapid | “There will be used individual intravenous insulin (actrapid) infusion to prevent non-intended hyperglycemia.” NCT01071772 ↗20“Insulin Aspart (NovoRapid®) Versus Human Insulin (Actrapid®), Used in a Multiple Injection Regimen” NCT00365170 ↗ “Insulin aspart (Novorapid, Novo Nordisk) and human insulin (Actrapid, Novo Nordisk) are used.” NCT01088451 ↗ “Basal (Monotard) insulin; ones a day Bolus (Actrapid) insulin; thrice a day” NCT01957930 ↗ “Actrapid: subcutaneous insulin/ Placebo A high dose (oral)” NCT07634770 ↗ “4 units (0.1 ml) of human soluble insulin (Actrapid)” NCT07432581 ↗ “Insulin (Actrapid) diluted in normal saline” NCT04877210 ↗ “Insulatard, Actrapid, Lantus, monotard” NCT00506194 ↗ “Intravenous insulin (actrapid)” NCT00764556 ↗ “Mealtime insulin (Actrapid)” NCT02138006 ↗ “Drug: Insulin (Actrapid)” NCT00505505 ↗ |
| Known as | Actrapid HM | “Continuous insulin infusion of 50 IU Actrapid HM (Novo Nordisk) in 50 ml NaCl (0.9% using a Perfusor-FM pump) will be started only when blood glucose levels exceeded 200 mg/dl...” NCT01016509 ↗ |
| Known as | Actrapid insulin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01213563 ↗ |
| Known as | Adrenocorticotropic hormone (ACTH) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02446886 ↗ |
| Known as | Afrezza | “Patients will receive TI (Afrezza) to be compared to RAA following a breakfast meal” NCT06535789 ↗10“Technosphere insulin (TI, Afrezza) -Treatment arm” NCT03143816 ↗ “Afrezza (insulin human) Inhalation Powder” NCT05243628 ↗ “Afrezza inhaled insulin low dose.” NCT03234491 ↗ |
| Known as | AIR inhaled insulin | “A study to compare Human Inhalation Powder (also known as AIR® Inhaled Insulin) (AIR® is a registered trademark of Alkermes, Inc.)with insulin glargine injections in patients...” NCT00437112 ↗3“preprandial human insulin inhalation powder (HIIP; AIR inhaled insulin)” PMID 17288697 ↗ Feb 2007 “starting with a fixed dose of HIIP (also known as AIR® Inhaled Insulin)” NCT00391209 ↗ “Human Insulin Inhalation Powder [also known as AIR® Inhaled Insulin]” NCT00355849 ↗ |
| Known as | BC222 insulin lispro | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03262116 ↗ |
| Known as | BHI30 | “a 30/70 (rapid/intermediate-acting) premixed suspension of the rapid-acting insulin analogue insulin aspart (BIAsp30) was compared with a similar premixed suspension of...” PMID 11009049 ↗ Aug 20001“BHI 30 (biphasic human insulin 30) administered subcutaneously (under the skin) twice daily (30 minutes before breakfast and dinner) + metformin.” NCT00807092 ↗ |
| Known as | biphasic human insulin 30 | “BHI 30 (biphasic human insulin 30) administered subcutaneously (under the skin) twice daily (30 minutes before breakfast and dinner) + metformin.” NCT00807092 ↗ |
| Known as | CP-464,005 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00527397 ↗ |
| Known as | Exubera | “Efficacy and Safety of Inhaled Human Insulin (Exubera) Compared With Subcutaneous Human Insulin in the Therapy of Adult Subjects With Type 1 or Type 2 Diabetes Mellitus and...” NCT00138671 ↗15“first inhaled human insulin (INH, Exubera (insulinhuman [rDNA origin])InhalationPowder) was approved for use in adult patients with type 1 diabetes mellitus (T1DM) or type 2...” PMID 16901335 ↗ Aug 2006 “Efficacy and Safety of Inhaled Human Insulin (Exubera) Compared With Subcutaneous Human Insulin” NCT00139659 ↗ “Exubera® (Insulin Dry Powder Pulmonary Inhaler)” NCT00150410 ↗ “The drug is called EXUBERA (inhaled insulin).” NCT00137046 ↗ “Inhaled Human Insulin (Exubera®)” NCT00391027 ↗ “Inhaled human insulin (EXUBERA™)” NCT00424411 ↗ “Inhaled Human Insulin (Exubera®)” NCT00356421 ↗ “Inhaled Human Insulin (Exubera)” NCT00367445 ↗ “Inhaled Human Insulin (Exubera)” NCT00437489 ↗ “Exubera (inhaled insulin)” NCT00246623 ↗ “Inhaled Insulin (Exubera)” NCT00282971 ↗ |
| Known as | Fast-acting human insulin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04824586 ↗ |
| Known as | fast-acting insulin human | “At the first treatment visit, a single dose of fast-acting insulin human at 0.2 IU/kg via IM (in the muscle) injection is administered.” NCT01269606 ↗ |
| Known as | HIIP | “A Phase 3, Open-Label, Parallel-Group Study to Compare Two Dosing Algorithms for Preprandial Human Insulin Inhalation Powder (HIIP) in Insulin-Naive Patients With Type 2...” NCT00391209 ↗2“preprandial human insulin inhalation powder (HIIP; AIR inhaled insulin)” PMID 17288697 ↗ Feb 2007 “LY041001 (HIIP)” NCT00099515 ↗ |
| Known as | Hlin | “The aim of this multicenter, prospective, randomized, crossover trial is to compare, in critical care patients receiving insulin infusion therapy (IIT), the pharmacodynamic of...” PMID 25466315 ↗ Oct 2014 |
| Known as | HR1799 | “Insulin human/Insuman Comb 25 (HR1799)” NCT01353469 ↗1“insulin human (HR1799)” NCT01630369 ↗ |
| Known as | Humalog | “160 IU insulin (Humalog) is administered intranasally using a metered spray bottle 15 minutes prior to the PET scan.” NCT05748990 ↗1“Insulin Humalog (generic name Lispro)” NCT01406496 ↗ |
| Known as | Human actrapid insulin | “Intralesional insulin injection (Human actrapid insulin 100 IU\\ml solution)” NCT06230146 ↗ |
| Known as | Human Inhalation Powder | “A study to compare Human Inhalation Powder (also known as AIR® Inhaled Insulin) (AIR® is a registered trademark of Alkermes, Inc.)with insulin glargine injections in patients...” NCT00437112 ↗ |
| Known as | human insulin | “Efficacy and Safety of Inhaled Human Insulin (Exubera) Compared With Subcutaneous Human Insulin in the Therapy of Adult Subjects With Type 1 or Type 2 Diabetes Mellitus and...” NCT00138671 ↗90“The active substance for oral application is human insulin, synthesized in a special non-disease-producing laboratory strain of Escherichia coli bacteria that has been...” NCT02620072 ↗ “The active substance for oral application is human insulin, synthesized in a special non-disease-producing laboratory strain of Escherichia coli bacteria that has been...” NCT02547519 ↗ “first inhaled human insulin (INH, Exubera (insulinhuman [rDNA origin])InhalationPowder) was approved for use in adult patients with type 1 diabetes mellitus (T1DM) or type 2...” PMID 16901335 ↗ Aug 2006 “Novolin R is a sterile, clear, aqueous, and colorless solution that contains human insulin (rDNA origin) 100 units/mL, glycerol 16 mg/mL, metacresol 3 mg/mL, zinc chloride...” NCT03811951 ↗ “Efficacy and Safety of Exubera (Inhaled Insulin) Compared With Subcutaneous Human Insulin Therapy in Adult Subjects With Type 1 Diabetes Mellitus: A Long-Term, Outpatient,...” NCT00137046 ↗ “3.0 of human insulin. single dose cartridges filled with 5 or 10 mg of Technosphere Inhalation Powder, containing 15 or 30 u of insulin” NCT00673621 ↗ “inhaled human insulin (Exubera [EXU] [Pfizer Inc., New York, NY] (insulin human [recombinant DNA origin]) inhalation powder)” PMID 19905885 ↗ Nov 2009 “a total of 16 sprays or 160 IU of fast-acting human insulin (Actrapid, Novo Nordisk A/S, Bagsvaerd, Denmark).” NCT02933645 ↗ “Efficacy and Safety of Inhaled Human Insulin (Exubera) Compared With Subcutaneous Human Insulin” NCT00139659 ↗ “Insulin aspart (Novorapid, Novo Nordisk) and human insulin (Actrapid, Novo Nordisk) are used.” NCT01088451 ↗ “simultaneous injections of pramlintide (Symlin®) and human insulin (Humulin®)” NCT03512236 ↗ “The active substance for oral application is human insulin.” NCT03364868 ↗ “Inhaled human insulin and Technosphere Powder” NCT01365117 ↗ “Subcutaneous Human Insulin Therapy” NCT00136916 ↗ “Human Insulin (Huminsulin® Normal)” NCT02213146 ↗ “Actrapid (human insulin)” NCT00654056 ↗ “Actrapid (human insulin)” NCT00653510 ↗ “3.0 U of human insulin.” NCT00674050 ↗ |
| Known as | Human Insulin Inhalation Powder | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00437112 ↗ |
| Known as | human insulin inhalation powder (HIIP) | “preprandial human insulin inhalation powder (HIIP; AIR inhaled insulin)” PMID 17288697 ↗ Feb 2007 |
| Known as | human isophane insulin | “NPH (neutral protamine Hagedorn) insulin (human isophane insulin)” PMID 33166419 ↗ Nov 2020 |
| Known as | Human rDNA Insulin | “Human rDNA Insulin (Insuget, local brand of Getz Pharma)” NCT05161741 ↗ |
| Known as | human recombinant Insulin | “Novolin R (human recombinant Insulin)” NCT00282594 ↗ |
| Known as | Human regular insulin | “2 U/kg bolus of insulin (Human regular insulin) to be administered IV followed by an infusion of 2 U/ kg/min.” NCT02746432 ↗9“Treatment with human regular insulin administered subcutaneously before breakfast, lunch and supper” NCT04690309 ↗ “human regular insulin (Novolin ge Toronto)” NCT00000620 ↗ |
| Known as | human regular insulin (Novolin ge Toronto) | “human regular insulin (Novolin ge Toronto)” NCT00000620 ↗ |
| Known as | human regular insulin (Novolin R) | “human regular insulin (Novolin R)” NCT00000620 ↗ |
| Known as | Human Regular U-500 Insulin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01774968 ↗ |
| Known as | Huminsulin | “Insulin Dosage form : intravenous infusion, infusion period 60 minutes Dosage: continuous dose of 0.5 mU/kg/min infused intravenously over 60 min; Insulin Lilly, Huminsulin,...” NCT00814008 ↗ |
| Known as | Huminsulin Normal | “Regular human insulin (Huminsulin® Normal) individualised single subcutaneous injection followed by test meal intake” NCT02739906 ↗1“Human Insulin (Huminsulin® Normal)” NCT02213146 ↗ |
| Known as | Huminsulin Regular | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00985712 ↗ |
| Known as | Humulin | “Commercially available U-500 Humulin (regular insulin) diluted 1:4 with dilution buffer composed of sterile water, EDTA and mannitol to achieve U-100 concentration.” NCT07090824 ↗8“simultaneous injections of pramlintide (Symlin®) and human insulin (Humulin®)” NCT03512236 ↗ “eg. Humulin, Lantus, Novalin” NCT02694289 ↗ “Regular Insulin (Humulin®)” NCT04074317 ↗ “Regular insulin (Humulin)” NCT00553488 ↗ “Insulin (Humulin)” NCT00646581 ↗ “Insulin (Humulin)” NCT07535827 ↗ |
| Known as | Humulin NPH | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04012775 ↗ |
| Known as | Humulin R | “Humulin® R is a polypeptide hormone structurally identical to human insulin synthesised through recombinant deoxyribonucleic acid (rDNA) technology in a non-pathogenic...” NCT04022317 ↗18“Types of insulin: insulin lispro (Humalog 100 IU/mL) as fast-acting insulin and regular insulin (Humulin R) as regular insulin (Eli Lilly and Company, Indianapolis, IN, USA).” NCT04783376 ↗ “Topical insulin (Humulin R) will be compounded under sterile conditions at a local pharmacy at a concentration of 25 IU / ml in sterile balanced saline solution (0.9%).” NCT05321251 ↗ “Intranasal insulin will be made prepared from Humulin® R [insulin injection, human biosynthetic (rDNA Origin) REGULAR; 10 mL/vial, manufactured by Eli Lilly].” NCT03915613 ↗ “those in group B will get insulin (Humulin R) subcutaneously whose dose can be adjusted within 24 hours according to blood sugar levels” NCT07582471 ↗ “Patients will receive 40 IU of intranasal insulin (Humulin R) via a metered nasal dispenser” NCT02729064 ↗ “regular insulin (Humulin R) when given intranasally (as drops in nostrils)” NCT05062785 ↗ “Regular insulin (Humulin-R), intranasal route” NCT04028960 ↗ “Humulin® R (regular insulin human)” NCT04022317 ↗ “nasal insulin (Humulin R®)” NCT05742243 ↗ |
| Known as | Humulin S | “Insulin (Humulin S)” NCT02205996 ↗ |
| Known as | Humulin U-100 | “Participants will administer 40 IU of Humulin® U-100 insulin four times per day with an intranasal delivery device.” NCT05006599 ↗ |
| Known as | Humulin-N | “3 injections of Humalog(r) daily with meals; 3 injections of Humulin N (r) daily on rising, mid-afternoon, and at bedtime” NCT01613807 ↗ |
| Known as | Humulin-RU-100 | “INTERVENTIONS: Participants received 40 IU of insulin (Humulin-RU-100; Lilly) or placebo (diluent) daily for 12 months (blinded phase) followed by a 6-month open-label extension phase.” PMID 32568367 ↗ Sep 20203“Insulin (Humulin® R U-100)” NCT01767909 ↗ “Insulin (Humulin® R U-100)” NCT05081219 ↗ “Insulin (Humulin® R U-100)” NCT05006599 ↗ |
| Known as | INH | “first inhaled human insulin (INH, Exubera (insulinhuman [rDNA origin])InhalationPowder) was approved for use in adult patients with type 1 diabetes mellitus (T1DM) or type 2...” PMID 16901335 ↗ Aug 2006 |
| Known as | Inhaled Human Insulin | “Efficacy and Safety of Inhaled Human Insulin (Exubera) Compared With Subcutaneous Human Insulin” NCT00139659 ↗ |
| Known as | Inhaled Insulin | “Inhaled Insulin (Exubera)” NCT00418522 ↗ |
| Known as | INI | “We aimed to determine the effects of intranasal insulin (INI) on cognition and motor performance in PD.” PMID 31022213 ↗ Apr 2019 |
| Known as | Insuget | “Human rDNA Insulin (Insuget, local brand of Getz Pharma)” NCT05161741 ↗ |
| Known as | Insuget 70/30 | “The investigator will recommend the dose of Insuget 70/30 (Local Insulin brand) and/or Insuget N (Local Insulin brand) and/or Insuget R (Local Insulin brand) as per standard...” NCT05161741 ↗ |
| Known as | Insuget N | “The investigator will recommend the dose of Insuget 70/30 (Local Insulin brand) and/or Insuget N (Local Insulin brand) and/or Insuget R (Local Insulin brand) as per standard...” NCT05161741 ↗ |
| Known as | Insuget R | “The investigator will recommend the dose of Insuget 70/30 (Local Insulin brand) and/or Insuget N (Local Insulin brand) and/or Insuget R (Local Insulin brand) as per standard...” NCT05161741 ↗ |
| Known as | insulin Actrapid | “insulin Actrapid” NCT02164032 ↗ |
| Known as | insulin aspart | “This will be a prospective open label study of 100 subjects who will be randomized to either an insulin aspart (study drug) infusion (intensive insulin therapy \[IIT arm\]) for...” NCT02054429 ↗ |
| Known as | insulin human | “Subjects will receive FIAsp combined with their pre-trial basal insulin (insulin human, insulin detemir or insulin glargine) treatment in combination with their pre-trial metformin.” NCT01850615 ↗15“At the first treatment visit, a single dose of fast-acting insulin human at 0.2 IU/kg via IM (in the muscle) injection is administered.” NCT01269606 ↗ “The test product is defined as Afrezza [insulin human] inhalation powder administered using the Afrezza inhaler.” NCT04849845 ↗ |
| Known as | insulin human isophane suspension | “10 persons to insulin human isophane suspension (Humulin N) twice daily plus regular human insulin (Humulin R) before meals.” NCT05768191 ↗ |
| Known as | insulin injection, human biosynthetic (rDNA Origin) REGULAR | “Intranasal insulin will be made prepared from Humulin® R [insulin injection, human biosynthetic (rDNA Origin) REGULAR; 10 mL/vial, manufactured by Eli Lilly].” NCT03915613 ↗ |
| Known as | insulin isophane | “NPH insulin (insulin isophane)” NCT01122979 ↗ |
| Known as | Insulin, Regular, Human | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04739371 ↗ |
| Known as | insulinhuman [rDNA origin] | “first inhaled human insulin (INH, Exubera (insulinhuman [rDNA origin])InhalationPowder) was approved for use in adult patients with type 1 diabetes mellitus (T1DM) or type 2...” PMID 16901335 ↗ Aug 2006 |
| Known as | Insuman Basal | “Neutral Protamine Hagedorn basal insulin: Insuman® Basal (100 I.U./ml) in TactiPen® re-usable pen” NCT00941369 ↗ |
| Known as | Insuman Comb 25 | “Insulin human/Insuman Comb 25 (HR1799)” NCT01353469 ↗ |
| Known as | Insuman Rapid | “Insulin (Insuman Rapid) is administered once as a bolus of 0,1 IU/kg.” NCT01919788 ↗ |
| Known as | Isophane insulin | “Intranasal isophane insulin administered twice daily. Each administration consists of two sprays of 10 IU (0.1 ml) in alternating nostrils, totalling to 40 IU per day.” NCT07532577 ↗2“Novolin N, Isophane insulin for injection (Recominant Human Insulin)(100IU/ml),cartridges 3.0ml.” NCT00772265 ↗ “Isophane insulin” NCT05565976 ↗ |
| Known as | Jusline | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00532766 ↗ |
| Known as | lente | “Insulin glargine, neutral protamine hagedorn (NPH) insulin, detemir, lente and ultralente were considered as basal insulin.” NCT01798706 ↗1“Participants will continue with current mixed insulin treatment using NPH , or lente, and regular insulin .” NCT01424046 ↗ |
| Known as | Lispro | “Insulin Humalog (generic name Lispro)” NCT01406496 ↗ |
| Known as | LY041001 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00099515 ↗ |
| Known as | Nasulin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00850161 ↗ |
| Known as | Neutral protamine Hagedorn | “Neutral Protamine Hagedorn basal insulin: Insuman® Basal (100 I.U./ml) in TactiPen® re-usable pen” NCT00941369 ↗4“The intervention is Neutral Protamine Hagedorn (NPH) insulin plus complete insulin orders (CIO).” NCT01184014 ↗ “insulin detemir versus neutral protamine Hagedorn (NPH) insulin in basal-bolus therapy” PMID 15220016 ↗ May 2004 “Neutral protamine Hagedorn (NPH) insulin was the reference therapy.” PMID 27887605 ↗ Nov 2016 “neutral protamine Hagedorn (NPH)” PMID 19017758 ↗ Nov 2008 |
| Known as | Neutral Protamine Hagedorn (NPH) | “A "coverage" dose of 0.1 unit/kg/day of Neutral Protamine Hagedorn (NPH) for each 10 mg of prednisone or its equivalent was given twice daily with the administration of the...” NCT01810952 ↗ |
| Known as | neutral protamine Hagedorn (NPH) insulin | “The purpose of this study was to compare the glycemic response to treatment with glargine U100 or neutral protamine Hagedorn (NPH) insulin in patients with type 2 diabetes...” PMID 31383366 ↗ Aug 2019 |
| Known as | neutral protamine Hagedorn insulin | “comparing insulin detemir with neutral protamine hagedorn insulin, both with insulin aspart, in women with type 1 diabetes planning a pregnancy (n = 306) or are already...” PMID 21557440 ↗ Sep 20111“regular insulin before meals and basal neutral protamine Hagedorn insulin twice daily (control).” PMID 21454236 ↗ Sep 2011 |
| Known as | Novolg 70/30 | “Insulin Novolg 70/30 per protocol titration” NCT00232583 ↗ |
| Known as | Novolin 30R | “Insulin human/Novolin® 30R” NCT01353469 ↗ |
| Known as | Novolin 50R | “Novolin 50R” NCT01833559 ↗ |
| Known as | Novolin N | “Novolin N” NCT01833559 ↗ |
| Known as | Novolin R | “Patients in continuous subcutaneous insulin infusion group received Human Insulin (Novolin-R, Novo Nordisk) with an insulin pump” NCT00147836 ↗11“Regular insulin (Novolin-R) 20 international units (10 units) in one nostril twice daily for 21 days, 100 µl volume.” NCT04251585 ↗ “It involves administration of intranasal insulin (Novolin R), an investigational medication” NCT03811951 ↗ “Novolin R human insulin, Novo Nordisk Inc. Plainsboro, NJ” NCT03526536 ↗ “Insulin (Novolin R) and Glutathione (INS-GSH)” NCT05266417 ↗ “Human Insulin (Novolin-R, Novo Nordisk)” NCT02956655 ↗ “Human Insulin Injection（NOVOLIN®R）” NCT07608692 ↗ “Regular Human Insulin (Novolin® R)” NCT00071448 ↗ “Novolin R” NCT01833559 ↗ |
| Known as | novolog | “Insulin infusion through the subcutaneous pump will be continued or long acting analog, novolog will be given as per home regimen.” NCT02328040 ↗1“Saline and insulin (NovoLog) will be ordered though the UT Student Health Services Pharmacy” NCT01145482 ↗ |
| Known as | NovoLog 70/30 | “Eligible patients were started on insulin NovoLog 70/30 and metformin 1,000 mg twice daily.” PMID 17362692 ↗ Mar 2007 |
| Known as | NovoRapid | “Subcutaneous insulin (100 U/ml, NovoRapid®; Novo Nordisk, Bagsvaerd, Denmark) delivery with an insulin pump” NCT02359617 ↗ |
| Known as | NPH | “OBJECTIVE: This randomized, controlled noninferiority trial aimed to compare the efficacy and safety of insulin detemir (IDet) versus neutral protamine Hagedorn (NPH) (both...” PMID 22851598 ↗ Jul 20122“insulin detemir versus neutral protamine Hagedorn (NPH) insulin in basal-bolus therapy” PMID 15220016 ↗ May 2004 “human insulin [NPH]” NCT00949442 ↗ |
| Known as | NPH human insulin | “GROUP 2 - NPH human insulin, three applications per day” NCT02451917 ↗ |
| Known as | NPH Insulin | “Insulin detemir is a basal insulin analog that causes less weight gain than other basal insulin formulations, including the current standard intermediate-long acting Neutral...” PMID 24739875 ↗ Apr 201433“CIT consisted of twice daily injections of premixed insulin (30% regular insulin, 70% NPH-insulin) before breakfast and dinner.” NCT00440284 ↗ “Neutral Protamine Hagedorn (NPH) Insulin Titration Regimen” NCT01683331 ↗ “Patients will receive NPH insulin in a once-daily regimen.” NCT02758522 ↗ “The NPH insulin vial is a 10 ml vial dosed at 100 IU/mL” NCT06999551 ↗ “Regular insulin and NPH insulin” NCT04834362 ↗ “NPH insulin” NCT02033889 ↗ “NPH Insulin” NCT00835861 ↗ |
| Known as | Premixed Insulin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04726657 ↗ |
| Known as | protaphane | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01269996 ↗ |
| Known as | Recombinant Human Insulin | “Actrapid, Regular insulin for injection (Recombinant Human Insulin) (100 IU/mL)in vials 10.0 ml” NCT00719108 ↗5“Capsule containing 75iu recombinant human insulin administered two times per day” NCT06473662 ↗ “Capsules oral insulin, 7.5 mg of recombinant human insulin crystals” NCT00004984 ↗ |
| Known as | Recominant Human Insulin | “Novolin N, Isophane insulin for injection (Recominant Human Insulin)(100IU/ml),cartridges 3.0ml.” NCT00772265 ↗ |
| Known as | regular human insulin | “A Phase 1, Randomized, 3-Way Crossover, Investigator Initiated Proof-of-Concept Study to Investigate Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Properties of Two...” NCT01201278 ↗26“This trial compared safety and efficacy - including parental treatment satisfaction - of two basal-bolus regimens [IAsp plus Neutral Protein Hagedorn (NPH) insulin vs. regular...” PMID 17850471 ↗ Oct 2007 “The purpose of the study is to compare the human insulin inhalation powder plus insulin glargine with injected insulin (regular human insulin or insulin lispro) plus insulin...” NCT00447213 ↗ “OBJECTIVE: To assess the safety and efficacy of insulin aspart (IAsp) versus regular human insulin (HI) in basal-bolus therapy with NPH insulin in pregnant women with type 1 diabetes.” PMID 17392539 ↗ Apr 2007 “Administer subcutaneous regular human insulin 30 to 60 minutes before meals, or administer insulin lispro within 15 minutes before meals.” NCT00063128 ↗ “regular human insulin was administered with pramlintide or placebo using separate infusion pumps in a fixed ratio (9 μg/unit).” PMID 30213882 ↗ Sep 2018 “10 persons to insulin human isophane suspension (Humulin N) twice daily plus regular human insulin (Humulin R) before meals.” NCT05768191 ↗ “Humulin® R U-500 (U500/mL), a highly concentrated regular human insulin, will be used as an open-label comparator.” NCT05754424 ↗ “receive AIR insulin or SC insulin (regular human insulin or insulin lispro) at mealtimes.” PMID 19772449 ↗ Sep 2009 “Regular Human Insulin (Novolin® R)” NCT00071448 ↗ |
| Known as | regular insulin | “bolus of 1-3 IU/kg regular insulin together with 0.5-1 gm/kg dextrose followed by an intravenous infusion of 0.2 to 1 IU/kg/hr of regular insulin and a dextrose infusion will...” NCT07451561 ↗58“Continuous intravenous regular insulin infusion will be adjusted to maintain glycemic levels at least below 150 mg/dl, and, in stable patients and ideally, between 80 and 120 mg/dl.” NCT00747279 ↗ “Commercially available U-500 Humulin (regular insulin) diluted 1:4 with dilution buffer composed of sterile water, EDTA and mannitol to achieve U-100 concentration.” NCT07090824 ↗ “three administrations of regular insulin or short acting insulin analogues before meals combined with long-acting insulin analogue glargine in the evening.” NCT01150617 ↗ “Participants will be assigned to receive regular insulin either 20 or 40 IU administered through an intranasal nebulizer-like device.” NCT04199767 ↗ “glucose-insulin-potassium (GIK) consists of 20% glucose (200 g/L), 66.7 U/L regular insulin and 80 mmol/L potassium chloride (KCl).” NCT01516138 ↗ “CIT consisted of twice daily injections of premixed insulin (30% regular insulin, 70% NPH-insulin) before breakfast and dinner.” NCT00440284 ↗ “Regular insulin (Novolin-R) 20 international units (10 units) in one nostril twice daily for 21 days, 100 µl volume.” NCT04251585 ↗ “Participants will continue with current mixed insulin treatment using NPH , or lente, and regular insulin .” NCT01424046 ↗ “using continuous intravenous insulin solutions (100 units regular insulin in 100 mL: normal saline)” PMID 21865944 ↗ Sep 2011 “Human insulin: NPH and regular insulin: 2/3 of total daily dose as NPH and 1/3 as regular insulin.” NCT02278913 ↗ “Regular insulin subcutaneously wil be given in three equally divided doses before each meal.” NCT02758522 ↗ “GIK solution (potassium 80 mEq and regular insulin 325 IU in 500 ml of 50% glucose)” PMID 22986417 ↗ Sep 2012 “In one-liter: Dextrose 30% + 80 mEq Potassium Chloride + 50 units Regular Insulin” NCT00091507 ↗ “Insulin was Regular Insulin administered intravenous bolus.” NCT01831154 ↗ “NPH (70%) plus regular insulin or insulin aspart (30%)” NCT00174668 ↗ “initial intraoperative I.V. bolus of regular insulin” PMID 26897443 ↗ Feb 2016 “Regular insulin injection diluted to 100U/ml” NCT01031888 ↗ “Regular insulin and NPH insulin” NCT04834362 ↗ “Regular insulin” NCT04542148 ↗ “Regular Insulin” NCT00835861 ↗ |
| Known as | Regular insulin ( Actrapid, 100 unit/mL0 Solution for injection, Insulin Human (rDNA), Novo Nordisk | “Regular insulin ( Actrapid, 100 unit/mL0 Solution for injection, Insulin Human (rDNA), Novo Nordisk” NCT02216799 ↗ |
| Known as | regular insulin human | “Humulin® R (regular insulin human)” NCT04022317 ↗ |
| Known as | Regular Novolin R | “Regular Novolin R” NCT04251585 ↗ |
| Known as | RHI | “regular human insulin (RHI)” PMID 21355716 ↗ Feb 20111“Regular Human Insulin (RHI)” NCT02269735 ↗ |
| Known as | sliding-scale regular insulin | “receive sliding-scale regular insulin (SSRI) alone” PMID 19336639 ↗ Apr 2009 |
| Known as | SSR insulin | “supplemental doses of sliding scale human regular (SSR) insulin” NCT00177398 ↗ |
| Known as | SSRI | “receive sliding-scale regular insulin (SSRI) alone” PMID 19336639 ↗ Apr 2009 |
| Known as | Technosphere Insulin | “AIM: To evaluate the effect of final HbA1c levels on the incidences of hypoglycaemia in participants with type 1 diabetes treated with inhaled Technosphere® Insulin or...” PMID 31811662 ↗ Dec 201928“A 3 Month, Randomized, Open Label, Multi-center Study of Technosphere/Insulin Compared to Insulin Aspart in Subjects With Type 1 Diabetes Mellitus Receiving Insulin Glargine” NCT00539396 ↗ “Technosphere® Insulin inhalation powder (TI) is an ultra-rapid-acting insulin administered via oral inhalation using a breath-powered inhaler.” NCT06535789 ↗ “Inhaled Technosphere Insulin Compared With Injected Prandial Insulin in Type 1 Diabetes: A Randomized 24-Week Trial.” PMID 26180109 ↗ Jul 2015 “Prandial Inhalation of Technosphere/Insulin in Combination With Metformin or Technosphere/Insulin Alone” NCT00332488 ↗ “Bioavailability of Technosphere® Insulin Versus Subcutaneous Regular Human Insulin in Type 2 Diabetes” NCT00511719 ↗ “Prandial Inhalation of Technosphere/Insulin Versus Subcutaneous Basal” NCT00308308 ↗ “Technosphere insulin (TI, Afrezza) -Treatment arm” NCT03143816 ↗ “Technosphere Insulin (TI) Inhalation Powder” NCT00674050 ↗ “Technosphere Insulin® Inhalation Powder” NCT00662857 ↗ “Technosphere® Insulin Inhalation Powder” NCT00308737 ↗ “Technosphere® Insulin (TI) Powder” NCT00757367 ↗ |
| Known as | Technosphere Insulin Inhalation Powder | “A Phase 1, Open-Label Study to Investigate the Effect of Albuterol (Salbutamol) and Fluticasone on the Pharmacokinetics of Inhaled Technosphere® Insulin Inhalation Powder in...” NCT00674050 ↗ |
| Known as | Technosphere() inhaled insulin | “Technosphere(®) inhaled insulin (MannKind Corp., Valencia, CA)” PMID 21999640 ↗ Oct 2011 |
| Known as | U-500R | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02588950 ↗ |
| Known as | USLINR | “Human Insulin Injection（USLIN®R）” NCT07608692 ↗ |
| Known as | ZJSRM2021 | “Efficacy and Safety of Recombinant Human Insulin Patch ZJSRM2021” NCT05089942 ↗ |
| Action | Activate | “as insulin activates peroxisome proliferator-activated receptor-alpha receptors” NCT00762190 ↗ |
| Modality | Protein / enzyme biologic | “The efficacy and safety of insulin aspart (IAsp), a rapid-acting human insulin analogue, were compared with regular human insulin (HI) as the bolus component of basal-bolus...” PMID 17888133 ↗ Oct 2007 |
| Route | Other | “intraarterial infusion of insulin” NCT00001624 ↗ |
| Target | IGF1R | “Insulin facilitates this in vitro mediated by the IGF-1 receptor.” PMID 25300286 ↗ Oct 2014 |